image
image | latex
string | filename
string |
|---|---|---|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{\textbf{Subject}} & \textbf{\textbf{LLEback}} & \textbf{\textbf{LLEhip}} & \textbf{\textbf{LLEknee}} & \textbf{\textbf{LLECOP}} & \textbf{\textbf{CLLE}} & \textbf{\textbf{Subject}} & \textbf{\textbf{LLEback}} & \textbf{\textbf{LLEhip}} & \textbf{\textbf{LLEknee}} & \textbf{\textbf{LLECOP}} & \textbf{\textbf{CLLE}} \\
\hline
f1 & 0.2732 & 0.5066 & 0.4790 & 0.4971 & 0.3124 & m1 & 0.2553 & 0.4237 & 0.4051 & 0.3282 & 0.2260 \\
\hline
f2 & 0.2174 & 0.3764 & 0.4544 & 0.4237 & 0.2959 & m2 & 0.1339 & 0.3227 & 0.2504 & 0.5113 & 0.2334 \\
\hline
f3 & 0.2278 & 0.1263 & 0.2151 & 0.4273 & 0.1355 & m3 & 0.1654 & 0.06458 & 0.2447 & 0.2414 & 0.2212 \\
\hline
f4 & 0.3640 & 0.2462 & 0.2774 & 0.4089 & 0.1494 & m4 & 0.4070 & 0.3934 & 0.4609 & 0.4235 & 0.0874 \\
\hline
f5 & 0.1243 & 0.2066 & 0.1985 & 0.2300 & 0.1109 & m5 & 0.2238 & 0.2821 & 0.3495 & 0.4351 & 0.1541 \\
\hline
f6 & 0.4022 & 0.4485 & 0.3913 & 0.2746 & 0.0744 & m6 & 0.4231 & 0.3992 & 0.3250 & 0.3363 & 0.1253 \\
\hline
f7 & 0.1885 & 0.3252 & 0.3707 & 0.4207 & 0.2323 & m7 & 0.1500 & 0.2818 & 0.2691 & 0.4999 & 0.1781 \\
\hline
f8 & 0.2599 & 0.2422 & 0.3232 & 0.2252 & 0.1043 & m8 & 0.2445 & 0.2595 & 0.5264 & 0.2858 & 0.3885 \\
\hline
f9 & 0.1305 & 0.4150 & 0.2204 & 0.3495 & 0.3562 & m9 & 0.1280 & 0.3823 & 0.3858 & 0.3662 & 0.3622 \\
\hline
f10 & 0.2169 & 0.3252 & 0.2463 & 0.3903 & 0.13721 & m10 & 0.1167 & 0.2128 & 0.4376 & 0.4359 & 0.4034 \\
\hline
\end{tabular}
\end{table}
|
PMC4381841_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
C16—H16B···O2i & 0.97 & 2.54 & 3.320 (4) & 137 \\
\hline
C22—H22A···O5i & 0.97 & 2.47 & 3.391 (3) & 159 \\
\hline
C22—H22B···O7i & 0.97 & 2.29 & 3.190 (4) & 154 \\
\hline
\end{tabular}
\end{table}
|
PMC3152101_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{(2007-08)} & \textbf{Ghana} & \textbf{Uganda} & \textbf{Kerala} & \textbf{Sri Lanka**} & \textbf{Lao} \\
\hline
Total Population (WHO) & 23,008,000 & 29,899,000 & 31,900,000 & 19,207,000 & 5,759,000 \\
\hline
Government health budget & $450,252,725 & $252,673,400 & $27,820,800 & $490,665,852 & NA \\
\hline
Government expenditure as \% of total health expenditure (WHO) & 34\% & 29\% & 19\% & 46\% & 20\% \\
\hline
Ring-fenced budget for public mental hospitals & $17,412,263 & $14,160,000 & $432,216 & $6,466,392 & NA \\
\hline
Number of public mental hospitals & 3 & 1 & 3 & 3 & 0 \\
\hline
Other ring-fenced budgets for mental health & None & $2,545,614 & $124,200 & $2,027,000 & None \\
\hline
Total ring-fenced budget for mental health & $17,412,263 & $16,705,614 & $556,416 & $8,473,392 & 0 \\
\hline
Per capita ring-fenced budget for mental health & $0.76 & $0.56 & $0.02 & $0.44 & None \\
\hline
Ring-fenced budget for mental health as \% of health budget & 3.9\% & 6.6\% & 2.0\% & 1.7\% & NA \\
\hline
Hospital budget as percentage of ring-fenced budget for mental health & 100\% & 85\% & 78\% & 76\% & NA \\
\hline
Government mental health spending per capita & $0.76 & $0.56 & $0.02 & $0.44 & NA \\
\hline
BasicNeeds Budget & $651,660 & $329,643 & NA & $478,126 & $197,783 \\
\hline
\end{tabular}
\end{table}
|
PMC2889860_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Supervised \% (n)} & \textbf{Unsupervised \% (n)} \\
\hline
Number of respondents & 211 & 190 \\
\hline
Mean age, years (95\% CI) & 38.1 (37.7–40.4), & 39.5 (37.1–41.9) \\
\hline
Sex \\
\hline
Males & 34.6 (73) & 36.8 (70) \\
\hline
Females & 65.4 (138) & 63.2 (120) \\
\hline
Educational background \\
\hline
None & 44.5 (94) & 53.7 (102) \\
\hline
Primary & 20.9 (44) & 16.8 (32) \\
\hline
Middle school, JSS & 29.4 (62) & 27.4 (52) \\
\hline
Technical/commercial/SSS/post Sec & 5.2 (11) & 2.1 (4) \\
\hline
Physical Examination \\
\hline
Mean weight, Kg (95\% CI) & 49.6 (48.5–50.7) & 49.7 (48.7–50.7) \\
\hline
Mean temperature (95\% CI) & 37.9 (37.8–38.0) & 38.0 (37.9–38.0) \\
\hline
Biochemical \\
\hline
Proportion with sexual parasite (\%) & 2.4 (5/211) & 3.2 (6/190) \\
\hline
Mean hemoglobin, g/dL (95\% CI) & 12.4 (12.1–12.6) & 12.4 (11.4–13.3) \\
\hline
Geometric mean ALT, U/L (95\% CI) & 9.0 (7.9, 10.2) & 8.7 (7.6, 10.1) \\
\hline
Geometric mean AST, U/L (95\% CI) & 35.0 (32.9, 37.1) & 35.9 (33.6, 38.3) \\
\hline
Geometric mean TBil, µmol/L (95\% CI) & 12.2 (11.1, 13.5) & 11.6 (10.3, 13.1) \\
\hline
Geometric mean Ure, mmol/L (95\% CI) & 3.1 (2.9, 3.3) & 2.8 (2.6, 3.0) \\
\hline
Geometric mean Cre, µmol/L ( 95\% CI) & 68.8 (66.2, 71.5) & 67.7 (65.4, 70.1) \\
\hline
\end{tabular}
\end{table}
|
PMC2836893_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Primary outcome} & \textbf{MeasurementInterview(i), self-report(s)} & \textbf{T0 baseline} & \textbf{T1 midtreatment} & \textbf{Within-session (1–8)} & \textbf{T2 posttreatment} & \textbf{T6 FU 6 months} & \textbf{T12 FU 12 months} \\
\hline
\multirow{2}{*}{PTSD} & CAPS (i) & x & & & x & x & x \\
\hline
PSS-SR (s) & x & & 1, 2, 3, 4, 5, 6, 7, 8 & x & x & x \\
\hline
\multirow{2}{*}{Adverse events} & TAEQ (s) & x & x & & x & x & x \\
\hline
AE session ratings (s) & & & 2 ,3 \\
\hline
\end{tabular}
\end{table}
|
PMC3667059_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Symptoms}} \\
\hline
\textbf{Stool Samples (n = 546)} & \textbf{Diarrhea N(\%)} & \textbf{Vomiting N(\%)} & \textbf{Diarrhea or vomiting} \\
\hline
MXPyV-positive (n = 18) & 10 (56\%) & 9 (50\%) & 11 (61\%) \\
\hline
MXPyV-negative (n = 528) & 271 (51\%) & 245 (46\%) & 317 (60\%) \\
\hline
P-value & 0.81 & 0.81 & 1.0 \\
\hline
\end{tabular}
\end{table}
|
PMC3498111_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Patient (n = 157)} & \textbf{Caregiver (n = 157)} \\
\hline
Age, mean (SD) & 76 (8) & 65 (13) \\
\hline
Females, n (\%) & 85 (54) & 104 (66) \\
\hline
Living alone (\%) & 53 (34) & 22 (14) \\
\hline
MMSE score, mean (SD) & 24 (2) & NA \\
\hline
EQ-5D score (self-assessed), mean (SD) & 0.85 (0.17) & 0.83 (0.17) \\
\hline
Occupational status, n (\%) \\
\hline
On pension & 148 (94) & 92 (59) \\
\hline
On early retirement & 4 (3) & 10 (6) \\
\hline
Working & 3 (2) & 49 (31) \\
\hline
Other (e.g. housewife) & 2 (1) & 6 (4) \\
\hline
Caregiver's relation to patient, n (\%) \\
\hline
Spouse & NA & 99 (63) \\
\hline
Son/daughter (in-law) & NA & 48 (31) \\
\hline
Other & NA & 10 (6) \\
\hline
\end{tabular}
\end{table}
|
PMC2789065_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\multicolumn{2}{c|}{\textbf{Study group}} & \textbf{status} & \textbf{n total (female)} & \textbf{age [years] (mean; SD)} & \textbf{[m/kg2] BMI (mean; SD)} & \textbf{BMI Z-score SD)a (mean;} \\
\hline
\textbf{detection: obesity trio genome- wide association study} & \textbf{extremely obese children and adolescents} & \textbf{index patients} & \textbf{424 (224)} & \textbf{13.20 (2.80)} & \textbf{31.93 (5.39)} & \textbf{4.22 (1.84)} \\
\hline
& parents of the obese children and adolescents & parents & 848 (424) & 42.32 (6.07) & 30.40 (6.44) & 1.66 (1.85) \\
\hline
\multirow{2}{*}{confirmation: obesity trios genotyped for four SNPs} & \textbf{extremely obese children and adolescents} & \textbf{index patients} & 363 (209) & 13.38 (3.40) & 32.46 (6.45) & 4.35 (2.15) \\
\hline
parents of the obese children and adolescents & parents & 726 (363) & 40.62 (5.92) & 30.42 (6.15) & 1.72 (1.81) \\
\hline
\end{tabular}
\end{table}
|
PMC2981522_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Dataset} & \textbf{Nemenyi zBA} & \textbf{Nemenyi zCA} & \textbf{Nemenyi zDA} \\
\hline
PBC & 4.849742 & 14.98224 & 26.24057 \\
\hline
CML & 2.182384 & 39.33487 & 25.82488 \\
\hline
Veteran & 4.78046 & 14.53191 & 15.39793 \\
\hline
\end{tabular}
\end{table}
|
PMC4465950_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Progression (\%)} & \textbf{Improvement (\%)} & \textbf{p-value} \\
\hline
Average of MSQLI components (median) & 34.9 & 30.0 \\
\hline
SF36 Physical Components & 37.3 & 32.2 & 0.91 \\
\hline
SF36 Mental Components & 43.2 & 25.4 & 0.04* \\
\hline
Modified Fatigue Impact Scale (MFIS) & 36.2 & 39.4 & 0.95 \\
\hline
MOS Pain Effects Scale (PES) & 34.4 & 31.2 & 0.95 \\
\hline
Sexual Satisfaction Scale (SSS) & 29.5 & 18.2 & 0.38 \\
\hline
Bladder Control Scale (BLCS) & 37.6 & 21.6 & 0.04* \\
\hline
Bowel Control Scale (BWCS) & 29.3 & 20.3 & 0.38 \\
\hline
Perceived Deficits Questionnaire (PDQ) & 34.9 & 34.9 & 1 \\
\hline
Impact of Visual Impairment Scale (IVIS) & 14.8 & 14.8 & 1 \\
\hline
Mental Health Inventory (MHI) & 38.1 & 31.7 & 0.78 \\
\hline
Modified MOS Social Support Survey (MSSS) & 32.5 & 30.0 & 0.95 \\
\hline
\end{tabular}
\end{table}
|
PMC3462180_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Worst histological diagnosis among positive colpo sites} & \multicolumn{8}{c|}{\textbf{Worst histological diagnosis among all colpo sites (\%, 95\% CI):}} & \textbf{Total no. of patients} \\
\hline
& \multicolumn{\textbf{2}}{c|}{\textbf{Normal}} & \multicolumn{\textbf{2}}{c|}{\textbf{LSIL}} & \multicolumn{\textbf{2}}{c|}{\textbf{HSIL}} & \multicolumn{\textbf{2}}{c|}{\textbf{Cancer}} \\
\hline
\textbf{No colpo positive sites} & \textbf{\textbf{2}\textbf{0}} & \textbf{(56, 38–\textbf{7}\textbf{2})} & \textbf{7} & (16, \textbf{7}–3\textbf{0}) & \textbf{2} & \textbf{(3, \textbf{0}.6–13)} & \textbf{0} & & \textbf{2}9 \\
\hline
\textbf{Normal} & 16 & (44, \textbf{2}8–6\textbf{2}) & 1\textbf{0} & (\textbf{2}\textbf{2}, 1\textbf{2}–3\textbf{7}) & 3 & (5, 1–15) & \textbf{0} & & \textbf{2}9 \\
\hline
\textbf{LSIL} & & & \textbf{2}8 & (6\textbf{2}, 4\textbf{7}–\textbf{7}6) & 3 & (5, 1–15) & \textbf{0} & & 31 \\
\hline
\textbf{HSIL} & & & & & 51 & (8\textbf{7}, \textbf{7}4–94) & \textbf{0} & & 51 \\
\hline
\textbf{Cancer} & & & & & & & 5 & (1\textbf{0}\textbf{0}) & 5 \\
\hline
\textbf{Total no. of patients} & 36 & & 45 & & 59 & & 5 & & 145 \\
\hline
\end{tabular}
\end{table}
|
PMC4427274_table_5
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Phenolic acids} & \textbf{Chemical structure} & \multirow{2}{*}{\textbf{Control (mg/g}} & \multicolumn{2}{c|}{\textbf{Fold of control}} \\
\hline
& & \textbf{JA} & \textbf{YE} \\
\hline
rosmarinic acid & & \multirow{2}{*}{2.89 $\pm$ 0.86} & \multirow{2}{*}{3.75} & \multirow{2}{*}{4.95} \\
\hline
(MW: 360.31 g/mol) \\
\hline
vanillic acid & & \multirow{2}{*}{0.31 $\pm$ 0.03} & \multirow{2}{*}{2.80} & \multirow{2}{*}{3.72} \\
\hline
(MW: 168.14 g/mol) \\
\hline
chlorogenic acid & & \multirow{2}{*}{0.07 $\pm$ 0.01} & \multirow{2}{*}{1.10} & \multirow{2}{*}{1.90} \\
\hline
(MW: 354.31 g/mol) \\
\hline
caffeic acid & & \multirow{2}{*}{0.58 $\pm$ 0.02} & \multirow{2}{*}{1.30} & \multirow{2}{*}{3.46} \\
\hline
(MW: 180.16 g/mol) \\
\hline
p-coumaric acid & & 0.04 $\pm$ 0.03.. & 2.40 & 3.50 \\
\hline
\multicolumn{5}{c|}{(MW: 164.16 g/mol)} \\
\hline
sinapic acid & & \multirow{2}{*}{0.14 $\pm$ 0.04} & \multirow{2}{*}{2.50} & \multirow{2}{*}{1.82} \\
\hline
(MW: 224.21 g/mol) \\
\hline
\end{tabular}
\end{table}
|
PMC3647086_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Value} & \textbf{V/H} & \textbf{V/A} & \textbf{A/H} \\
\hline
Baseline & 16,192.40 & 8690.13 & 12,694.89 \\
\hline
Discount rate \\
\hline
Low: 0 \% & 9136.23 & 4899.12 & 6528.41 \\
\hline
High: 6 \% & 18,887.19 & 10,127.14 & 15,888.91 \\
\hline
Generic Substitution \\
\hline
Cheapest generics & 30,021.13 & 21,881.33 & 12,870.17 \\
\hline
Marginal price (further price decrease −75 \%) & 41,707.74 & 51,015.44 & 17,685.29 \\
\hline
Health resources cost \\
\hline
50 \% decrease & 16,188.30 & 8766.81 & 12,518.28 \\
\hline
50 \% increase & 16,202.98 & 8620.55 & 12,875.81 \\
\hline
\multicolumn{2}{c|}{Price estimation based on alternative sickness fund coverage} \\
\hline
Deterministic & 30,021.13 & 15,609.78 & 11,069.45 \\
\hline
Probabilistic (mean) & 26,105.42 & 18,295.66 & 11,298.31 \\
\hline
Age group \\
\hline
40 years & 12,976.54 & 7133.45 & 16,440.77 \\
\hline
60 years & 19,162.85 & 10,037.84 & 11,961.30 \\
\hline
70 years & 23,846.40 & 11,883.61 & 9960.84 \\
\hline
Clinical characteristics \\
\hline
All patients diabetics & 16,477.38 & 8711.76 & 13,137.42 \\
\hline
Prior CVD & 15,342.43 & 7966.95 & 11,985.83 \\
\hline
\end{tabular}
\end{table}
|
PMC4474457_table_6
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Enzyme} & \textbf{Substrate} & \multicolumn{2}{c|}{\textbf{Specific activity (U/mg protein)}} \\
\hline
& & \textbf{No compound} & \textbf{+ Compound} \\
\hline
Glutathone-S-transferase & CDNB & 0.253 $\pm$ 0.015 & _ \\
\hline
Catalase & H2O2 & 1.396 $\pm$ 0.068 & 1.031 $\pm$ 0.064 \\
\hline
Superoxide dismutase & Epinephrine & 0.204 $\pm$ 0.05 & _ \\
\hline
Glucose 6 phosphate dehydrogenase & NADP & 387.9 $\pm$ 26 & _ \\
\hline
Glutathione reductase & NADPH & 39.77 $\pm$ 4.8 & _ \\
\hline
Glutathione peroxidase & NADPH & 0.00022 & _ \\
\hline
\end{tabular}
\end{table}
|
PMC4647299_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Year} & \multicolumn{2}{c|}{\textbf{Whole population}} & \multicolumn{2}{c|}{\textbf{Male}} & \multicolumn{2}{c|}{\textbf{Female}} \\
\hline
& \textbf{OR (95\%CI)} & \textbf{\textbf{\textbf{P-Value}}} & \textbf{\textbf{OR(95\%CI)}} & \textbf{\textbf{\textbf{P-Value}}} & \textbf{\textbf{OR(95\%CI)}} & \textbf{\textbf{\textbf{P-Value}}} \\
\hline
2006 & 1.00[Reference] & & 1.00[Reference] & & 1.00[Reference] \\
\hline
2007 & 1.14(1.04–1.25) & 0.003 & 1.03(0.93–1.15) & 0.54 & 1.34(1.16–1.56) & ,0.001 \\
\hline
2008 & 1.63(1.50–1.77) & ,0.001 & 1.43(1.29–1.58) & ,0.001 & 2.02(1.76–2.32) & ,0.001 \\
\hline
2009 & 2.24(2.07–2.42) & ,0.001 & 1.93(1.75–2.12) & ,0.001 & 2.86(2.51–3.25) & ,0.001 \\
\hline
2010 & 2.29(2.12–2.47) & ,0.001 & 1.93(1.76–2.13) & ,0.001 & 3.01(2.64–3.43) & ,0.001 \\
\hline
\end{tabular}
\end{table}
|
PMC3400670_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \textbf{Type 1 error rate 1990} & \textbf{Type 1 error rate 2013} & \textbf{Significant p-values 1990} & \textbf{Significant p-values 2013} & \textbf{Reconstructed 1990/2013 ratio of fractions} \\
\hline
p0.001–p0.009 & 0.008 & 0.009 & 1,899 & 50,338 & 6.44 \\
\hline
p0.011–p0.019 & 0.008 & 0.014 & 581 & 17,072 & 7.14 \\
\hline
p0.021–p0.029 & 0.008 & 0.018 & 408 & 13,706 & 8.16 \\
\hline
p0.031–p0.039 & 0.008 & 0.022 & 327 & 12,755 & 9.47 \\
\hline
p0.041–p0.049 & 0.008 & 0.028 & 279 & 13,262 & 11.56 \\
\hline
\end{tabular}
\end{table}
|
PMC4525697_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Fabric} & \textbf{UDC (\%)} & \textbf{Peak numbers} & \textbf{Avg. bending index} & \textbf{Bending variation index (\%)} & \textbf{Avg. peak height(mm)} & \textbf{Peak height variation index (\%)} & \textbf{Avg. peak width (mm)} & \textbf{Peak width variation index (\%)} \\
\hline
1 & 76.45 & 6 & 2.077 & 7.39 & 40.126 & 8.073 & 40.256 & 5.922 \\
\hline
2 & 44.84 & 4 & 7.901 & 17.861 & 63.326 & 12.996 & 57.027 & 6.62 \\
\hline
3 & 89.7 & 6 & 2.577 & 3.823 & 45.716 & 14.627 & 49.082 & 8.125 \\
\hline
4 & 75.6 & 6 & 2.684 & 6.419 & 50.709 & 6.002 & 46.061 & 6.265 \\
\hline
5 & 80.27 & 7 & 2.594 & 5.474 & 44.889 & 4.155 & 52.939 & 5.651 \\
\hline
6 & 92.78 & 7 & 2.387 & 2.686 & 40.115 & 6.657 & 55.764 & 7.513 \\
\hline
7 & 48.87 & 5 & 1.811 & 12.179 & 43.628 & 11.083 & 43.096 & 12.532 \\
\hline
8 & 59.31 & 6 & 2.124 & 12.95 & 41.789 & 10.013 & 57.331 & 8.652 \\
\hline
9 & 87.83 & 7 & 2.193 & 4.622 & 42.692 & 7.015 & 49.032 & 7.201 \\
\hline
10 & 56.52 & 5 & 2.222 & 11.608 & 47.591 & 10.564 & 48.64 & 9.562 \\
\hline
11 & 54.3 & 5 & 2.148 & 8.001 & 50.058 & 11.688 & 49.18 & 9.628 \\
\hline
12 & 69.57 & 5 & 2.263 & 13.022 & 47.391 & 7.877 & 51.315 & 11.526 \\
\hline
13 & 60.87 & 5 & 2.385 & 12.722 & 45.051 & 9.233 & 60.281 & 7.654 \\
\hline
14 & 72.91 & 7 & 2.263 & 8.975 & 39.924 & 4.444 & 47.908 & 9.854 \\
\hline
15 & 66.45 & 7 & 2.265 & 10.816 & 41.352 & 7.85 & 52.5 & 7.485 \\
\hline
16 & 77.36 & 7 & 2.743 & 11.884 & 50.413 & 5.077 & 46.261 & 5.598 \\
\hline
17 & 57.68 & 6 & 2.317 & 10.651 & 42.783 & 10.498 & 57.755 & 8.486 \\
\hline
18 & 64.77 & 6 & 2.397 & 10.822 & 45.359 & 6.139 & 43.143 & 3.634 \\
\hline
19 & 63.26 & 6 & 2.656 & 10.179 & 45.924 & 8.187 & 54.166 & 7.233 \\
\hline
20 & 84.52 & 7 & 2.748 & 7.881 & 42.506 & 5.211 & 51.351 & 10.621 \\
\hline
\end{tabular}
\end{table}
|
PMC4657933_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Predictor variable} & \textbf{Variable type} & \textbf{Adjusted OR (CI)} & \textbf{P value} \\
\hline
Age & Continuous & 1.04 (1.02–1.06) & ,0.0001 \\
\hline
Location (Gumarey vs. Sogan-Godud) & Dichotomous & 3.3 (1.5–7.2) & 0.003 \\
\hline
Drank raw milk & Dichotomous & 2.9 (1.3–6.3) & 0.006 \\
\hline
\end{tabular}
\end{table}
|
PMC3156691_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Drug} & \textbf{Duration} \\
\hline
Standard Therapy \\
\hline
INH & 6 mo \\
\hline
RIF & 6 mo \\
\hline
EMB & 2 mo \\
\hline
PZA & 2 mo \\
\hline
No INH \\
\hline
RIF & 6 mo \\
\hline
EMB & 6 mo \\
\hline
PZA & 6 mo \\
\hline
No RIF \\
\hline
INH & 12 mo \\
\hline
EMB & 12 mo \\
\hline
MFX & 12 mo \\
\hline
PZA & 2 mo \\
\hline
No PZA \\
\hline
INH & 9 mo \\
\hline
RIF & 9 mo \\
\hline
EMB & 2 mo \\
\hline
No INH or RIF \\
\hline
PZA & 18 mo \\
\hline
EMB & 18 mo \\
\hline
MFX & 18 mo \\
\hline
AMK & 6 mo \\
\hline
\end{tabular}
\end{table}
|
PMC4540488_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{1. Competencies} & \textbf{Module Objectives: Student should be able to} & \textbf{Assessment} \\
\hline
\multirow{7}{*}{Knowledge} & 1. Describe care of expectant mother (antenatal care) & MCQs, SAQs \\
\hline
2. Describe changes in maternal physiology in normal pregnancy & MCQs \\
\hline
3. Describe pillars of Safe Motherhood \\
\hline
4. Describe parameters to be evaluated at each visit Describe assessment of fetal growth & MCQs \\
\hline
5. Explain the rationale for different investigations & MCQS \\
\hline
6. Describe methods of family planning, their respective side effects, and contraindications & MCQS \\
\hline
7. Describe strategies to prevent maternal mortality & MCQS, SAQ \\
\hline
\multirow{3}{*}{Skills} & 1. Perform maternal counseling & IPE \\
\hline
2. Perform counseling in care of expectant mother & MCQ \\
\hline
3. Perform counseling in family planning & IPE \\
\hline
\multirow{2}{*}{Scholarship} & Perform literature search about common causes of maternal mortality \\
\hline
Search for ways of decreasing maternal mortality in your community \\
\hline
\multirow{3}{*}{Community Health Advocacy} & 1. Screen for maternal illnesses in community & MCQs \\
\hline
2. Provide nutritional guidance for expectant mother and child & MCQs, SAQs \\
\hline
3. Conduct routine investigation for antenatal care \\
\hline
\multirow{2}{*}{Reflective Practitioner} & 1. Foresee complications & MCQS \\
\hline
2. Devise ways to decrease pregnancy-related complications encountered in the community \\
\hline
Professionalism & Provide punctuality and empathy; respect patients’ rights. \\
\hline
\multirow{3}{*}{Communication skills} & 1. Provide counseling \\
\hline
2. Explain use of supplements and vaccinations during pregnancy & IPE \\
\hline
3. Explain family planning methods best for different couples & IPE \\
\hline
Collaborative skills & 1. Collaborate with community for safe pregnancy and delivery For preventing prenatal conditions predisposing to infant morbidity \\
\hline
\multirow{3}{*}{Ethical practice} & 1. Advocate against illegal abortions \\
\hline
2. Refrain from prescription of costly supplements \\
\hline
3. Prevent repeated ultrasound \\
\hline
\multirow{2}{*}{Evidence-based lifelong learning} & 1. Do appropriate literature search for evidence \\
\hline
2. perform community-based interventions to reduce maternal mortality \\
\hline
\end{tabular}
\end{table}
|
PMC3180395_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Population-attributable Fraction \% (95\%CI)}} \\
\hline
& \textbf{Men} & \textbf{Women} & \textbf{Total} \\
\hline
\textbf{Total} AMI events (both fatal and non-fatal) & 81.8 (81.3-82.2) & 84.1 (82.8-85.0) & 82.4 (81.9-82.8) \\
\hline
\textbf{Total} non-infarction events (both fatal and non-fatal) & 81.5 (80.9-82.0) & 83.5 (81.9-84.7) & 82.1 (81.5-82.6) \\
\hline
\textbf{Total} stroke events (both fatal and non-fatal) & 66.6 (65.7-67.4) & 57.6 (56.4-58.8) & 62.4 (61.6-63.1) \\
\hline
\textbf{Total} events (both fatal and non-fatal) & 76.8 (76.2-77.4) & 70.7 (69.4-71.7) & 74.6 (74.0-75.1) \\
\hline
\textbf{Total} costs* & 77.5 (76.9-78.0) & 72.0 (70.7-73.1) & 75.5 (75.0-76.0) \\
\hline
DALY† \textbf{Total} & 76.0 (75.5-76.4) & 65.8 (65.0-66.5) & 70.7 (70.2-71.1) \\
\hline
PYLL‡ \textbf{Total} & 76.5 (75.9-76.9) & 69.6 (68.6-70.5) & 73.4 (72.9-73.9) \\
\hline
\end{tabular}
\end{table}
|
PMC2970607_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Topographical distribution} & \textbf{GMFCS} & \textbf{Individuals} \\
\hline
Diparesis & III & 6 \\
\hline
Hemiparesis & II & 4 \\
\hline
Quadriparesis & IV & 5 \\
\hline
Quadriparesis & V & 5 \\
\hline
Total & & 20 \\
\hline
\end{tabular}
\end{table}
|
PMC3599980_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
F2 Refinement on & Primary atom site location: structure-invariant direct methods \\
\hline
Least-squares matrix: full & Secondary atom site location: difference Fourier map \\
\hline
R[F2 2σ(F2)] > = 0.060 & Hydrogen site location: inferred from neighbouring sites \\
\hline
wR(F2) = 0.140 & H-atom parameters constrained \\
\hline
S = 0.96 & 1/[σ2(Fo 2) (0.0432P)2] w = + 2 2)/3 where P = (Fo + 2Fc \\
\hline
3825 reflections & (Δ/σ)max = 0.001 \\
\hline
227 parameters & Å−3 Δρmax = 0.31 e \\
\hline
0 restraints & Å−3 Δρmin = −0.34 e \\
\hline
\end{tabular}
\end{table}
|
PMC3201529_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Sex} & \textbf{Age at diagnosis (Y)} & \textbf{Site} & \textbf{Initial management} & \textbf{Size of initial lesion} & \textbf{Time to LR/treatment of PD (M)} & \textbf{Treatment for progression/LR} \\
\hline
\textbf{F} & 47 & igh & \textbf{GTR} & 6.0 × 6.0 × 6.0 & 20 & Reop RT + \textbf{GTR} \\
\hline
\textbf{F} & 76 & igh & \textbf{GTR} & 4.0 × 3.0 × 1.5 & 20.2 & Reop RT + \textbf{GTR} \\
\hline
M & 65 & \textbf{F}orearm & \textbf{GTR} & 15.0 × 5.0 × 5.0 & 36.7 & Reop RT + \textbf{GTR} \\
\hline
\textbf{F} & 73 & igh & \textbf{GTR} & 6.0 × 9.0 & 124.2 & \textbf{GTR} + postop RT \\
\hline
\textbf{F} & 45 & igh & \textbf{GTR} & 10.5 × 6.5 × 2 & 133.8 & \textbf{GTR} + postop RT \\
\hline
\end{tabular}
\end{table}
|
PMC3562577_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Species} & \textbf{Strain} & \textbf{(\%)a Nucleotide Identity} & \textbf{Percentage of orthologous genes} \\
\hline
Pseudomonas fuscovaginae-like & IRRI 6609 & 100 & 100 \\
\hline
Pseudomonas fuscovaginae-like & IRRI 7007 & 91.93 & 90.19 \\
\hline
Pseudomonas fuscovaginae-like & S-E1 & 86.39 & 80.19 \\
\hline
Pseudomonas fuscovaginae & CB98818 & 84.03 & 74.17 \\
\hline
Pseudomonas fuscovaginae & UPB7036 & 84.21 & 76.22 \\
\hline
Pseudomonas fuscovaginae & DAR 77795 & 83.89 & 71.13 \\
\hline
Pseudomonas fuscovaginae & DAR 77800 & 84.52 & 60.56 \\
\hline
Pseudomonas fuscovaginae & ICMP 5940 & 84.04 & 71.44 \\
\hline
\end{tabular}
\end{table}
|
PMC4589537_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{The Different Regions} & \textbf{1–100 ns} & \textbf{101–200 ns} & \textbf{201–300 ns} & \textbf{301–400 ns} & \textbf{401–500 ns} \\
\hline
NUMintraHB > 0, Lhelix > 0, Lsheet = 0; Cited as VI & 0.23 (0.11) & 0.04 (0) & 0 (0) & 0 (0) & 0 (0) \\
\hline
NUMintraHB > 0, Lhelix > 0, Lsheet > 0; Cited as V & 0.17 (0.04) & 0.04 (0) & 0 (0) & 0 (0) & 0 (0) \\
\hline
NUMintraHB > 0, Lhelix = 0, Lsheet = 0; Cited as IV & 0.04 (0.04) & 0.01 (0.01) & 0 (0.03) & 0 (0) & 0 (0.01) \\
\hline
NUMintraHB > 0, Lhelix = 0, Lsheet > 0; Cited as III & 0.48 (0.69) & 0.37 (0.54) & 0.32 (0.39) & 0.23 (0.41) & 0.16 (0.41) \\
\hline
NUMintraHB = 0, Lhelix > 0, Lsheet = 0 & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 0 (0) \\
\hline
NUMintraHB = 0, Lhelix > 0, Lsheet > 0 & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 0 (0) \\
\hline
NUMintraHB = 0, Lhelix = 0, Lsheet > 0; Cited as II & 0.07 (0.10) & 0.53 (0.40) & 0.67 (0.48) & 0.75 (0.49) & 0.82 (0.49) \\
\hline
NUMintraHB = 0, Lhelix = 0, Lsheet = 0; Cited as I & 0 (0.02) & 0 (0.04) & 0 (0.09) & 0 (0.09) & 0.01 (0.08) \\
\hline
\end{tabular}
\end{table}
|
PMC4519842_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Measure} & \textbf{T0} & \textbf{T1} & \textbf{T2} & \textbf{Each session} \\
\hline
Demographics (Young people and parents) & X \\
\hline
Young people: K10, RADS-2, Keyes, Brief COPE, FRI, OCNI, CAMM, AFQ-Y & X & X & X \\
\hline
Parents: K10, FRI & X & X & X \\
\hline
Satisfactiona & & X \\
\hline
Fidelity & & & & X \\
\hline
\end{tabular}
\end{table}
|
PMC4564955_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{Source} & \textbf{P(perm)} & \textbf{df} & \textbf{SS} & \textbf{MS} & \textbf{Pseudo-F} \\
\hline
\multirow{5}{*}{Assemblage} & DIS & 0.16 & 6 & 34079 & 5679.8 & 1.182 \\
\hline
FARM(DIS) & 0.25 & 2 & 50086 & 25043 & 1.1734 \\
\hline
IS (DIS) & 0.0001 & 11 & 2.33E+05 & 21215 & 11.052 \\
\hline
FARM(DIS)xIS (DIS) & 0.0001 & 21 & 1.01E+05 & 4824.6 & 2.5134 \\
\hline
Residuals & & 173 & 3.24E+05 & 1919.6 \\
\hline
\end{tabular}
\end{table}
|
PMC4378911_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \textbf{Control} & \multicolumn{4}{c|}{\textbf{Acute respiratory distress syndrome}} & \textbf{¶P-value} \\
\hline
& & \textbf{Total} & \textbf{Mild} & \textbf{Moderate} & \textbf{Severe} \\
\hline
Number & 26 & 79 & 24 & 28 & 27 \\
\hline
Age, years & 54.00 $\pm$ 13.77 & 55.03 $\pm$ 14.42 & 55.17 $\pm$ 15.45 & 53.36 $\pm$ 13.34 & 57.63 $\pm$ 15.57 & 0.714 \\
\hline
Gender, male/female, n & 14/12 & 44/35 & 13/11 & 15/13 & 16/11 & 0.971 \\
\hline
kg/m2 BMI, & 22.44 $\pm$ 3.53 & 24.03 $\pm$ 4.13 & 24.72 $\pm$ 4.98 & 24.67 $\pm$ 3.84 & 24.26 $\pm$ 3.93 & 0.150 \\
\hline
Cause of ARDS \\
\hline
Pneumonia & & 25 & 6 & 9 & 10 \\
\hline
Non-pulmonary sepsis & & 19 & 4 & 8 & 7 \\
\hline
Trauma & & 23 & 9 & 6 & 8 \\
\hline
Aspiration & & 5 & 2 & 2 & 1 \\
\hline
Multiple transfusions & & 4 & 2 & 2 \\
\hline
Others & & 3 & 1 & 1 & 1 \\
\hline
APACHE II score & & 22 (20 to 26) & 20 (18 to 22) & 23 (21 to 26)* & 25 (22 to 27)* & <0.001 \\
\hline
SOFA score & & 11.0 (10.0 to 13.0) & 9.5 (7.0 to 11.8) & 11.0 (10.0 to 13.0)* & 12.0 (11.0 to 13.0)* & <0.001 \\
\hline
Lung injury score & & 2.3 (2.1 to 2.8) & 2.0 (1.9 to 2.1) & 2.3 (2.1 to 2.5)* & 3.2)*# 2.9 (2.7 to & <0.001 \\
\hline
PaO2/FiO2 (mmHg) & & 138 (76 to 222) & 258 (223 to 273) & 139 (120 to 158)* & 79)*# 67 (59 to & <0.001 \\
\hline
CRP, mg/L & 4.97 (3.83 to 6.12) & 135.84 (116.83 to 156.79) & 116.69 (104.17 to 133.33) & 130.97 (123.40 to 154.45) & 156.85 (143.59 to 185.36)* & <0.001 \\
\hline
PCT, ng/mL & 0.04 (0.02 to 0.06) & 1.56 (1.24 to 1.83) & 1.24 (1.05 to 136) & 1.47 (1.27 to 1.66) & 2.61)*# 2.04 (1.62 to & <0.001 \\
\hline
109/L Leukocytes, & 6.8 (5.6 to 8.2) & 12.9 (11.2 to 14.8) & 11.8 (10.5 to 12.8) & 12.4 (10.7 to 13.7) & 17.6)*# 15.3 (13.6 to & <0.001 \\
\hline
109/L Monocytes, & 0.58 (0.46 to 0.69) & 1.05 (0.92 to 1.23) & 0.95 (0.84 to 1.13) & 1.04 (0.88 to 1.23) & 1.12 (1.04 to 1.1.26)* & <0.001 \\
\hline
109/L Lymphocytes, & 3.09 (2.80 to 3.52) & 5.35 (4.25 to 6.47) & 4.24 (3.93 to 4.96) & 5.24 (4.19 to 6.06)* & 7.45)*# 6.72 (5.69 to & <0.001 \\
\hline
CD4+ Th17 cells, \% of & 0.71 (0.59 to 0.94) & 4.27 (3.67 to 6.02) & 3.54 (3.17 to 3.94) & 4.16 (3.96 to 4.54)* & 6.91)*# 6.42 (5.96 to & <0.001 \\
\hline
CD4+ Treg cells, \% of & 3.11 (2.70 to 3.44) & 5.37 (4.98 to 6.07) & 4.82 (4.50 to 5.18) & 5.46 (5.25 to 5.81)* & 6.57)*# 6.18 (5.82 to & <0.001 \\
\hline
Th17/Treg ratio & 0.25 $\pm$ 0.09 & 0.86 $\pm$ 0.20 & 0.74 $\pm$ 0.12 & 0.77 $\pm$ 0.10 & 0.18*# 1.01 $\pm$ & <0.001 \\
\hline
IL-6, pg/mL & 11.70 $\pm$ 1.31 & 758.33 $\pm$ 70.03 & 721.53 $\pm$ 54.43 & 763.62 $\pm$ 76.96* & 785.56 $\pm$ 62.36* & <0.001 \\
\hline
IL-17, pg/mL & 20.27 $\pm$ 4.12 & 199.59 $\pm$ 68.12 & 139.42 $\pm$ 25.51 & 204.75 $\pm$ 37.64* & 78.08*# 247.72 $\pm$ & <0.001 \\
\hline
IL-10, pg/mL & 123.04 $\pm$ 20.53 & 131.19 $\pm$ 19.94 & 137.8 $\pm$ 19.17 & 132.49 $\pm$ 20.14 & 124.17 $\pm$ 18.87 & 0.029 \\
\hline
TGF-β1, pg/mL & 193.48 $\pm$ 46.48 & 209.92 $\pm$ 51.00 & 219.30 $\pm$ 61.84 & 200.30 $\pm$ 41.77 & 211.55 $\pm$ 49.25 & 0.264 \\
\hline
28-day mortality, n, \% & & 32 (40.5\%) & 7 (29.17\%) & 12 (42.86\%) & 13 (48.15\%) \\
\hline
\end{tabular}
\end{table}
|
PMC4355972_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Extracts} & \multicolumn{3}{c|}{\textbf{Extract content}} \\
\hline
& \textbf{Polyphenols (gallic acid equivalents)} & \textbf{Flavonoids (Quercitin equivalents)} & \textbf{Tannins (Tannic acid equivalents)} \\
\hline
Chloroform extract & 104.41 & - & - \\
\hline
Ethyl acetate extract & 227.75 & 264.57 & 136.64 \\
\hline
Methanol extract & 157.47 & 114.57 & 116 \\
\hline
TOF extract & 372 .47 & 494.57 & 163.73 \\
\hline
\end{tabular}
\end{table}
|
PMC3462690_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Principals}} & \multicolumn{2}{c|}{\textbf{Teachers}} \\
\hline
& \textbf{\textbf{N}} & \textbf{\textbf{\%}} & \textbf{\textbf{N}} & \textbf{\textbf{\%}} \\
\hline
School food policy (n = 70) \\
\hline
Rules & 40 & 57.1 \\
\hline
Recommendations & 26 & 37.1 \\
\hline
\textbf{\textbf{N}}o food policy & 4 & 5.7 \\
\hline
Written food policy (n = 64) \\
\hline
Yes & 57 & 89.1 \\
\hline
no & 7 & 10.9 \\
\hline
Activities undertaken to inform parents about food policy (n = 62)* \\
\hline
School magazine & 46 & 74.2 \\
\hline
Informal meetings & 35 & 56.5 \\
\hline
Parent’s evening & 5 & 8.1 \\
\hline
Parent’s council & 2 & 3.2 \\
\hline
Interview on admission to school & 7 & 11.3 \\
\hline
Compliance with school food policy (n = 57) \\
\hline
Yes & & & 45 & 78.9 \\
\hline
Varying & & & 5 & 8.7 \\
\hline
\textbf{\textbf{N}}o & & & 7 & 12.2 \\
\hline
Enforcement of school food policy (n = 62)* \\
\hline
Addressing child & & & 19 & 30.6 \\
\hline
Addressing parent & & & 8 & 12.9 \\
\hline
Addressing both parent and child & & & 27 & 43.5 \\
\hline
Addressing in classroom & & & 6 & 9.7 \\
\hline
Child not allowed to consume the unhealthy food & & & 8 & 12.9 \\
\hline
\textbf{\textbf{N}}o set approach & & & 6 & 9.7 \\
\hline
Parental appreciation of school food policy (n = 62) \\
\hline
Good & & & 54 & 87.1 \\
\hline
Varying & & & 7 & 11.2 \\
\hline
Poor & & & 1 & 1.6 \\
\hline
Attention for nutrition by the school (n = 74) \\
\hline
Insufficient & 6 & 8.1 \\
\hline
Sufficient & 65 & 87.8 \\
\hline
\textbf{\textbf{N}}o opinion & 3 & 4.1 \\
\hline
Role of the school in fostering healthy eating habits among children (principals n = 73; teachers n = 72) \\
\hline
Parents primarily responsible, school supportive role & 54 & 74.0 & 64 & 88.9 \\
\hline
School and parents equally responsible & 12 & 16.4 & 4 & 5.6 \\
\hline
School no responsibility & 7 & 9.5 & 4 & 5.6 \\
\hline
\end{tabular}
\end{table}
|
PMC3637056_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{CI} & \textbf{YPTB Locus} & \textbf{Definition} & \textbf{50-90 Cluster ID} & \textbf{Total non-pathogens} & \textbf{Total pathogens} & \textbf{Pathogen strains} \\
\hline
0.01 & 2410 & Magnesium transport ATPase mgtB & 1035 & 3 & 8 & Bme, Bma, Bp \\
\hline
0.03 & 2913 & Deoxyribopyrimidine photolyase phrB & 2801 & 0 & 6 & Vc \\
\hline
0.06 & 2705 & Putative manganese transport protein mntH & 1611 & 3 & 8 & Ba, Bma, Bp \\
\hline
0.12 & 3827 & Outer membrane biogenesis protein & 2798 & 0 & 5 & - \\
\hline
0.13 & 0181 & Putative protohaeme IX biogenesis protein hemY & 3642 & 0 & 5 & - \\
\hline
0.16 & 0756 & Superoxide dismutase C sodC & 1306 & 0 & 9 & Bme, Cb, Ft, Vc \\
\hline
0.39 & 1340 & Lysine specific permease cadR & 563 & 2 & 9 & Ba, Bma, Bp, Ft \\
\hline
0.42 & 0242 & Glycerophosphoryl diester phosphodiesterase glpQ & 2411 & 0 & 7 & Bma, Bp \\
\hline
0.45 & 2699 & Hypothetical protein & 3924 & 0 & 7 & Bma, Bp \\
\hline
0.76 & 1424 & Hypothetical protein & 1031 & 3 & 9 & Bma, Bp, Ft, Vc \\
\hline
0.87 & 3166 & Thiol:disulphide interchange protein dscB & 3283 & 0 & 5 & - \\
\hline
2.38 & 0188 & Frataxin-like protein cyaY & 2139 & 2 & 6 & Vc \\
\hline
3.15 & 3505 & Stringent starvation protein sspB & 1207 & 3 & 7 & Cb, Vc \\
\hline
ND & 1167 & Phosphate starvation protein & 3911 & 0 & 6 & - \\
\hline
ND & 1251 & Ecotin & 3380 & 0 & 6 & - \\
\hline
ND & 2026 & MviN-like protein & 1296 & 3 & 9 & Bma, Bp, Cb \\
\hline
ND & 2995 & Putative surface antigen & 2296 & 2 & 7 & Vc \\
\hline
\end{tabular}
\end{table}
|
PMC2774872_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{5}{c|}{\textbf{High-risk group}} & \textbf{p-value} \\
\hline
& \textbf{Total (n=264)} & \textbf{18-49 Years (n=38)} & \textbf{50-64 Years (n=112)} & \textbf{65-74 Years (n=86)} & \textbf{$\geq$75 Years (n=28)} \\
\hline
Duration of hospitalization & 20.1$\pm$19.3 & 22.0$\pm$16.5 & 21.7$\pm$21.9 & 17.3$\pm$14.4 & 19.4$\pm$24.2 & 0.41 \\
\hline
ICU admission, no. (\%) & 84 (31.8) & 13 (34.2) & 33 (29.5) & 28 (32.6) & 10 (35.7) & 0.9 \\
\hline
Duration of ICU admission & 3.4$\pm$8.7 & 3.2$\pm$7.2 & 2.7$\pm$6.2 & 3.1$\pm$7.5 & 6.7$\pm$17.8 & 0.19 \\
\hline
Case fatality rate, no. (\%)* & 89/252 (35.3) & (21.1)a 8/38 & (30.8)a 33/107 & (40.0)a 30/82 & (72.0)b 18/25 & < 0.01 \\
\hline
Time to death (days) & 9.7$\pm$8.5 & 9.6$\pm$5.9 & 10.6$\pm$9.1 & 8.6$\pm$7.9 & 9.7$\pm$9.9 & 0.85 \\
\hline
Direct medical costs per case† & & & & & & 0.76 \\
\hline
\multirow{2}{*}{Mean (95\% CI)} & US $7,667 & US $6,990 & US $7,135 & US $8,609 & US $7,880 \\
\hline
(6,395-8,938) & (4,464-9,516) & (5,746-8,524) & (5,648-11,569) & (2,297-13,462) \\
\hline
\multirow{4}{*}{Median (IQR)} & US $5,552 & US $6,749 & US $5,612 & US $5,472 & US $3,262 \\
\hline
(2,567-9,872) & (2,474-9,948) & (3,007-9,650) & (3,278-10,442) & (1,532-10,034) \\
\hline
\multicolumn{5}{c|}{Moderate-risk group} & \textbf{p-value} \\
\hline
Total (n=423) & 18-49 years (n=91) & 50-64 years (n=147) & 65-74 years (n=108) & $\geq$75 years (n=77) \\
\hline
Duration of hospitalization & 17.8$\pm$26.1 & 15.3$\pm$15.7 & 17.7$\pm$17.3 & 19.0$\pm$24.4 & 19.0$\pm$45.3 & 0.76 \\
\hline
ICU admission, no. (\%) & 191 (45.2) & 35 (38.5) & 68 (46.3) & 46 (42.6) & 42 (54.5) & 0.19 \\
\hline
Duration of ICU admission & 5.3$\pm$20.8 & 3.2$\pm$6.4 & 5.2$\pm$10.9 & 4.7$\pm$8.9 & 9.0$\pm$44.9 & 0.33 \\
\hline
Case fatality rate, no. (\%)* & 110/397 (27.7) & 19/88 (21.6) & 37/144 (25.7) & 28/96 (29.2) & 26/69 (37.7) & 0.14 \\
\hline
Time to death (days) & 7.4$\pm$6.8 & 6.3$\pm$5.3 & 8.8$\pm$7.7 & 7.1$\pm$6.1 & 6.5$\pm$6.9 & 0.45 \\
\hline
Direct medical costs per case† & & & & & & 0.03 \\
\hline
\multirow{2}{*}{Mean (95\% CI)} & US $7,037 & $5,404a US & $8,756b US & $6,964ab US & $5,730a US \\
\hline
(6,120-7,955) & (4,191-6,617) & (6,650-10,861) & (5,395-8,532) & (4,423-7,037) \\
\hline
\multirow{4}{*}{Median (IQR)} & US $4,517 & US $3,685 & US $4,956 & US $4,664 & US $4,679 \\
\hline
(2,432-7,961) & (2,405-6,805) & (2,797-10,003) & (2,402-9,499) & (1,879-7,057) \\
\hline
\multicolumn{5}{c|}{Low-risk group} & \textbf{p-value} \\
\hline
Total (n=283) & 18-49 years (n=86) & 50-64 years (n=61) & 65-74 years (n=72) & $\geq$75 years (n=64) \\
\hline
Duration of hospitalization & 19.0$\pm$25.6 & 19.0$\pm$20.9 & 21.9$\pm$21.2 & 19.9$\pm$27.4 & 15.4$\pm$32.3 & 0.55 \\
\hline
ICU admission, no. (\%) & 139 (49.1) & 33 (38.4) & 31 (50.8) & 40 (55.6) & 35 (54.7) & 0.11 \\
\hline
Duration of ICU admission & 6.8$\pm$13.8 & 5.9$\pm$13.6 & 8.3$\pm$14.3 & 6.8$\pm$13.1 & 6.8$\pm$14.7 & 0.78 \\
\hline
(\%)* Case fatality rate, no. & 82/260 (31.5) & (13.6)a 11/81 & (22.4)a 13/58 & (43.1)b 28/65 & (53.6)b 30/56 & < 0.01 \\
\hline
Time to death (days) & 7.9$\pm$9.0 & 10.2$\pm$15.4 & 9.2$\pm$10.3 & 9.3$\pm$8.1 & 5.3$\pm$5.2 & 0.26 \\
\hline
Direct medical costs per case† & & & & & & 0.69 \\
\hline
\multirow{2}{*}{Mean (95\% CI)} & US $7,903 & US $6,849 & US $8,528 & US $8,557 & US $8,090 \\
\hline
(6,675-9,131) & (4,931-8,766) & (5,715-11,342) & (6,239-10,875) & (4,727-11,453) \\
\hline
\multirow{2}{*}{Median (IQR)} & US $4,968 & US $4,448 & US $5,726 & US $5,896 & US $3,367 \\
\hline
(2,187-9,613) & (1,856-8,574) & (3,443-8,858) & (2,178-11,733) & (1,879-9,308) \\
\hline
\end{tabular}
\end{table}
|
PMC3660270_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Process} & \multicolumn{5}{c|}{\textbf{Removal (\%)}} \\
\hline
& \textbf{COD} & \textbf{TKN} & \textbf{P*} & \textbf{Cu} & \textbf{# Cr} \\
\hline
Fenton & 69.6 & 33.2 & 96.3 & 35.7 & 72.7 \\
\hline
Fenton-like & 65.9 & 19 & 95.4 & 28.6 & 63.6 \\
\hline
Photo-Fenton & 83.2 & 16.8 & 96.9 & 50 & 100 \\
\hline
\end{tabular}
\end{table}
|
PMC3555129_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multirow{3}{*}{\textbf{Dysmorphic oocytes N = 119}} & \multirow{3}{*}{\textbf{Normal oocytes N = 77}} & \multirow{3}{*}{\textbf{Dysmorphic vs. Normal Diff1/RR2 3 / IRR [95\% CI] P-value}} & \multirow{3}{*}{\textbf{oocytes4 Dysmorphic vs. Normal Difference1/RR2 3 / IRR [95\% CI] P-value}} \\
\hline
\\
\hline
\\
\hline
Age & 35.5 (3.9) & 34.3 (4.1) & 1.2 [0.05,2.4] \\
\hline
Mean (SD) & & & P = 0.040 \\
\hline
AMH ng/ml & 2.5 (2.0) & 2.3 (1.5) & 0.2 [−0.9, 1.2] & −0.1 [−1.2, 0.9] \\
\hline
Mean (SD) & & & P = 0.762 & P = 0.795 \\
\hline
FSH IU/l & 6.0 (2.5) & 6.8 (2.3) & −0.8 [−1.7, 0.2] & −0.8 [−1.7, 0.2] \\
\hline
Mean (SD) & & & P = 0.115 & P = 0.120 \\
\hline
Total Gonadotropin dose IU & 3847.4 (1791.8) & 3128.2 (1842.4) & 719 [184, 1254] & 525 [12, 1038] \\
\hline
Mean (SD) & & & P = 0.009 & P = 0.045 \\
\hline
Peak Estradiol Pg/ml & 2760.6 (1346.4) & 3157.4 (1377.6) & −396.8 [−802.7, 9.1] & −345.5 [−753.8, 62.8] \\
\hline
Mean (SD) & & & P = 0.055 & P = 0.097 \\
\hline
Oocytes retrieved per cycle & 10.3 (5.4) & 12.8 (5.4) & −2.5 [−4.0, −0.9] & −2.2 [−3.7, −0.6] \\
\hline
Mean (SD) & & & P = 0.002 & P = 0.007 \\
\hline
\% M2 oocytes & 78.0\% (17.9\%) & 81.3 (17.9\%) & −3.3\% [−8.4\%, 1.9\%] & −3.4\% [−8.6\%, 1.8\%] \\
\hline
Mean (SD) & & & P = 0.214 & p = 0.196 \\
\hline
Long Agonist cycles & 45\% & 68\% & \multirow{3}{*}{0.005} \\
\hline
Short Antagonist cycles & 25\% & 18\% \\
\hline
Short Flare cycles & 31\% & 14\% \\
\hline
\end{tabular}
\end{table}
|
PMC4355133_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Bruker SMART APEXII CCD area-detector diffractometer & 4015 independent reflections \\
\hline
Radiation source: fine-focus sealed tube & 3390 reflections with I > 2σ(I) \\
\hline
graphite & Rint = 0.030 \\
\hline
φ and ω scans & θmax = 30.1°, θmin = 2.1° \\
\hline
Absorption correction: multi-scan (SADABS; Bruker, 2009) & h = −12→12 \\
\hline
Tmin = 0.292, Tmax = 0.644 & k = −12→12 \\
\hline
10644 measured reflections & l = −14→14 \\
\hline
\end{tabular}
\end{table}
|
PMC3052152_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Enraf–Nonius CAD-4 diffractometer & Rint = 0.052 \\
\hline
Radiation source: fine-focus sealed tube & θmax = 26.0º \\
\hline
Monochromator: graphite & θmin = 1.6º \\
\hline
T = 294(2) K & h = −18→16 \\
\hline
ω/2θ scans & k = 0→8 \\
\hline
Absorption correction: ψ scan (North et al., 1968) & l = 0→21 \\
\hline
Tmin = 0.969, Tmax = 0.984 & 3 standard reflections \\
\hline
3472 measured reflections & every 120 min \\
\hline
3340 independent reflections & intensity decay: none \\
\hline
1835 reflections with I > 2σ(I) \\
\hline
\end{tabular}
\end{table}
|
PMC2961278_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Exams performed} & \textbf{Number of patients} \\
\hline
EGD only & 8 \\
\hline
EGD + colonoscopy & 6 \\
\hline
Colonoscopy only & 1 \\
\hline
EGD + colonoscopy + VCE & 2 \\
\hline
EGD + VCE & 1 \\
\hline
EGD + colonoscopy + enteroscopy + VCE & 2 \\
\hline
\end{tabular}
\end{table}
|
PMC3299279_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Standard group} & \textbf{Training group} \\
\hline
Number & 44 & 37 \\
\hline
Gender & 24 m / 20 f & 23 m / 14 f \\
\hline
Age (years) & 65 $\pm$ 8 & 63 $\pm$ 11 \\
\hline
(kg/m2) BMI & 25 $\pm$ 5 & 24 $\pm$ 5 \\
\hline
FEV1 (\%predicted) & 45 $\pm$ 13 & 47 $\pm$ 13 \\
\hline
ITGV (\%predicted) & 140 $\pm$ 35 & 150 $\pm$ 43 \\
\hline
6MWT (m) & 429 $\pm$ 92 & 415 $\pm$ 83 \\
\hline
6MWT (\%predicted) & 67 $\pm$ 13 & 63 $\pm$ 13 \\
\hline
Workmax (Watt) & 75 $\pm$ 23 & 84 $\pm$ 30 \\
\hline
VO2max (l/min) & 1.05 $\pm$ 0.364 & 1.05 $\pm$ 0.398 \\
\hline
CPET time (min) & 8.9 $\pm$ 2.5 & 9.4 $\pm$ 3.4 \\
\hline
Peak heart rate during CPET (1/min) & 116 $\pm$ 18 & 121 $\pm$ 11 \\
\hline
SF-12 PCS & 33 $\pm$ 9 & 35 $\pm$ 10 \\
\hline
SF-12 MCS & 52 $\pm$ 13 & 53 $\pm$ 12 \\
\hline
SGRQ symptoms & 55 $\pm$ 20 & 44 $\pm$ 23 \\
\hline
SGRQ activity & 60 $\pm$ 20 & 57 $\pm$ 16 \\
\hline
SGRQ impact & 36 $\pm$ 17 & 31 $\pm$ 17 \\
\hline
SGRQ total & 47 $\pm$ 17 & 41 $\pm$ 15 \\
\hline
\end{tabular}
\end{table}
|
PMC3502444_table_1
|
|
\begi\textbf{\textbf{\textbf{n}}}{table}
\ce\textbf{\textbf{\textbf{n}}}teri\textbf{\textbf{\textbf{n}}}g
\label{tab:tablelabel}
\begi\textbf{\textbf{\textbf{n}}}{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hli\textbf{\textbf{\textbf{n}}}e
& \multicolum\textbf{\textbf{\textbf{n}}}{3}{c|}{\textbf{Voltage depe\textbf{\textbf{\textbf{n}}}de\textbf{\textbf{\textbf{n}}}ce of activatio\textbf{\textbf{\textbf{n}}}}} & \multicolum\textbf{\textbf{\textbf{n}}}{3}{c|}{\textbf{Voltage depe\textbf{\textbf{\textbf{n}}}de\textbf{\textbf{\textbf{n}}}ce of i\textbf{\textbf{\textbf{n}}}activatio\textbf{\textbf{\textbf{n}}}}} & \multicolum\textbf{\textbf{\textbf{n}}}{3}{c|}{\textbf{Recovery from i\textbf{\textbf{\textbf{n}}}activatio\textbf{\textbf{\textbf{n}}}}} \\
\hli\textbf{\textbf{\textbf{n}}}e
& \textbf{\textbf{V1/2 (mV)}} & \textbf{\textbf{K}} & \textbf{\textbf{\textbf{n}}} & \textbf{\textbf{V1/2 (mV)}} & \textbf{\textbf{K}} & \textbf{\textbf{\textbf{n}}} & \textbf{(ms) τf} & \textbf{(ms) τs} & \textbf{\textbf{\textbf{n}}} \\
\hli\textbf{\textbf{\textbf{n}}}e
PD\textbf{\textbf{K}}1F/F 8W & −40.44$\pm$0.68 & 4.82$\pm$0.14 & 27 & −77.21$\pm$0.67 & −6.14$\pm$0.07 & 28 & 5.15$\pm$0.28 & 51.51$\pm$2.40 & 26 \\
\hli\textbf{\textbf{\textbf{n}}}e
PD\textbf{\textbf{K}}1F/F 8W αMHC-Cre & −38.37$\pm$0.95 & 4.61$\pm$0.21 & 35 & −76.65$\pm$0.85 & −5.61$\pm$0.0.05 & 34 & 4.36$\pm$0.19* & 49.92$\pm$1.72 & 32 \\
\hli\textbf{\textbf{\textbf{n}}}e
PD\textbf{\textbf{K}}1F/F 11 W & −39.61$\pm$0.68 & 4.37$\pm$0.21 & 16 & −75.09$\pm$1.17 & −6.19$\pm$0.08 & 14 & 6.22$\pm$0.17 & 69.32$\pm$1.47 & 13 \\
\hli\textbf{\textbf{\textbf{n}}}e
PD\textbf{\textbf{K}}1F/F 11W αMHC-Cre & −41.14$\pm$0.61 & 5.07$\pm$0.15 & 28 & −79.02$\pm$0.56* & −6.17$\pm$0.11 & 20 & 5.98$\pm$0.44 & 60.04$\pm$1.93* & 14 \\
\hli\textbf{\textbf{\textbf{n}}}e
\e\textbf{\textbf{\textbf{n}}}d{tabular}
\e\textbf{\textbf{\textbf{n}}}d{table}
|
PMC4363661_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable category} & \multicolumn{3}{c|}{\textbf{Tumor risk grade}} \\
\hline
& \textbf{Low (n = 13)} & \textbf{Intermediate(n = 8)} & \textbf{High (n = 19)} & \textbf{P value} \\
\hline
Age, years & 57.5$\pm$13.3 & 61.5$\pm$19.4 & 58.4$\pm$12.5 & 0.814 \\
\hline
Gender, n \\
\hline
Male & 5 & 1 & 12 & 0.046* \\
\hline
Female & 8 & 7 & 7 \\
\hline
Tumor size, cm & 3.2$\pm$1.0 & 5.9$\pm$2.1 & 9.6$\pm$4.0 & < .001* \\
\hline
Mitotic count, /50 HPF & 2.1$\pm$1.3 & 4.9$\pm$3.5 & 27.5$\pm$35.2 & 0.013* \\
\hline
SUVmax & 4.3$\pm$3.2 & 5.4$\pm$2.7 & 10.9$\pm$5.2 & .001* < \\
\hline
\end{tabular}
\end{table}
|
PMC4625049_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{P. fluorescens strain} & \textbf{SBW25} & \textbf{Pf0-1} & \textbf{Pf-5*} \\
\hline
Number of bases & 6,722,539 bp & 6,438,405 bp & 7,074,893 bp \\
\hline
Number of CDSs & 6,009 & 5,741 & 6,144 \\
\hline
Pseudogenes & 88 & 9 & NA \\
\hline
Coding percentage & 88.3\% & 90\% & 88.7\% \\
\hline
\%GC & 60.5 & 60.62 & 63.3 \\
\hline
tRNAs & 66 & 73 & 71 \\
\hline
rRNA genes (clusters) & 16 (5) & 19 (6) & 15 (5) \\
\hline
Intergenic repeat families & 6 (with a total of 1,199 repeats) & 9 (with a total of 231 repeats) & 5 (with a total of 748 repeats) \\
\hline
\end{tabular}
\end{table}
|
PMC2718517_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Method of the model class} & \textbf{Task description} & \textbf{External software typically called by the class} \\
\hline
\multirow{4}{*}{normalize} & Structural standardization & Standardizer [17] \\
\hline
Change ionization status (to a given pH) & RDKit [15] \\
\hline
2D to 3D transform & *Moka [20,21] \\
\hline
Check if the compound was present in the training series & *CORINA [22,23] \\
\hline
\multirow{3}{*}{extract} & Compute molecular descriptors & PaDel [16] \\
\hline
Extract biological properties from the input structures & *Pentacle [24,25] \\
\hline
& *ADRIANA Code [26] \\
\hline
\multirow{2}{*}{build} & Build a predictive model & R [18] \\
\hline
Validate the model evaluating it goodness-of-fit and predictive quality (by cross-validation) \\
\hline
\multirow{2}{*}{predict} & Produce a predicted value for the biological property of interest & R [18] \\
\hline
Asses the reliability of the prediction \\
\hline
\end{tabular}
\end{table}
|
PMC4358905_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{5}{c|}{\textbf{Pyrosequencing-specific minor SNP frequencies}} \\
\hline
\textbf{Single Founder} & \textbf{1–2\%} & \textbf{2–5\%} & \textbf{5–10\%} & \textbf{10–20\%} & \textbf{20–50\%} \\
\hline
Gag & 63.23 & 21.65 & 7.22 & 4.81 & 3.09 \\
\hline
gp120 & 56.60 & 27.72 & 7.92 & 3.96 & 3.80 \\
\hline
Nef & 42.25 & 25.13 & 10.43 & 7.75 & 14.44 \\
\hline
Multiple Founder & \textbf{1–2\%} & \textbf{2–5\%} & \textbf{5–10\%} & \textbf{10–20\%} & \textbf{20–50\%} \\
\hline
Gag & 46.51 & 18.60 & 9.30 & 13.95 & 11.63 \\
\hline
gp120 & 42.28 & 17.45 & 12.08 & 7.38 & 20.81 \\
\hline
Nef & 20.65 & 8.70 & 3.26 & 0.00 & 67.39 \\
\hline
\end{tabular}
\end{table}
|
PMC4552882_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\multicolumn{3}{c|}{\textbf{Objective 1. Determine the benefits of different integrated models to increase range, uptake and quality of selected SRH and HIV services and to diversify the profile of clients.}} \\
\hline
\textbf{Results/Outcomes} & \textbf{Indicators} & \textbf{Data source} \\
\hline
Feasibility of linking services demonstrated & Number of internal and external referrals, Number of staff updated in HIV counseling and testing Number of staff updated in HIV BCC prevention, Facilities have adequate equipment and supplies & Service statistics Provider interviews Facility inventory \\
\hline
Provision of linked services to clients & Clients received CT in FP consultation, Clients referred for ART, Clients referred for other services, Number of referrals attended, Proportion of population demanding integrated services, Proportion of population accessing integrated services, Proportion of services users giving integration as a reason for choice of clinic & Client exit Provider interview Cohort Community Survey \\
\hline
Increased \% of eligible HIV+ women starting to use ART & Proportion of women reaching referral site clients know their CD4 counts & Service statistics Cohort \\
\hline
Increased uptake of range of SRH services including integrated CT, FP, PNC and STI screening services & \% FP clients accessing more than one service Proportion of population accessing more than one service at last FP or PNC visit & Service statistics Exit /Cohort Community Survey \\
\hline
Increased quality of a range of SRH services & \% clients receiving minimum level of quality services & Client – provider interaction, exit interview \\
\hline
Increase in number and diversity of clients & \% men and women using component services Proportion of clients using component services by age, SES and gender & Community Service Statistics Client exit /CPI \\
\hline
Increased numbers of clients screened/managed for STIs & \% FP clients accessing separate/integrated services & Service statistics Client Flow Cohort \\
\hline
Increased in new and repeat FP clients testing for HIV & & Service statistics Cohort \\
\hline
Improved attitudes of service providers towards HIV+ clients & \% Providers indicating non discriminatory attitudes \% Clients recommending services to others & Provider interview Cohort survey Community Survey \\
\hline
\multicolumn{2}{c|}{Objective 2. Determine the impact of different pregnancies.} & HIV related stigma and unintended \\
\hline
Reduction in reported HIV risk behaviors among HIV negative & HIV positive clients & Condom use at last sex; Number of partners in past 12 months Received STI/HIV counseling Consistent condom use reported Use of condoms with another FP method (dual protection) & Cohort Client Exit Community Survey \\
\hline
Reduced incidence of unintended pregnancies & \% women who become pregnant (incidence) \% women reporting planned pregnancy \% women with correct knowledge of fertile period \% of population who report unintended pregnancy in last 12 months & Cohort Client Exit Community Survey \\
\hline
Increased duration of contraceptive use among HIV negative & HIV positive clients & Ever/current use of FP method Discontinuation FP rates in 12 months Ability to achieve fertility goals & Cohort survey \\
\hline
Improved attitudes of service providers towards HIV+ clients & Proportion of providers indicating non discriminatory attitudes towards HIV positive clients & Provider interview \\
\hline
Reduced stigma at health facilities. & Clients reporting positive experience of CT process \% clients reporting unacceptable stigmatizing behavior by providers & Community and Cohort survey \\
\hline
Decreased stigmatization at community level of HIV services if integrated with FP RH services & Perceived barriers to accessing services: costs, distance, quality, waiting times, stigma surrounding service & Community survey Cohort survey \\
\hline
\multicolumn{2}{c|}{Objective 3: Establish the efficiency of using of existing infrastructure and human resources.} & services in terms of: cost, utilization \\
\hline
Total resource requirements and unit costs of intervention & Cost per eligible client receiving ART, Cost per person-month of receiving ART Cost per client counseled, tested and receiving results Cost per client receiving each service component & Economic study \\
\hline
\end{tabular}
\end{table}
|
PMC3529107_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Total no.} & \textbf{Grade 3-4 (\%)} \\
\hline
Parity \\
\hline
0 & 1261 & 38.2 \\
\hline
1 $\geq$ & 8283 & 36.2 \\
\hline
a P-value & & 0.17 \\
\hline
Parous women: \\
\hline
1 & 1446 & 34.8 \\
\hline
2 & 3767 & 35.7 \\
\hline
3 & 2100 & 36.4 \\
\hline
$\geq$ 4 & 970 & 40.1** \\
\hline
a P-value & & 0.045 \\
\hline
unadjustedb OR, & & 1.1** \\
\hline
adjustedb,c,d OR, & & 1.1** \\
\hline
(yr)d Age at first birth \\
\hline
<20 yr & 1008 & 37.7 \\
\hline
20 - 24 yr & 3672 & 37.7 \\
\hline
25 - 29 yr & 2491 & 35.0 \\
\hline
30 yr $\geq$ & 1110 & 32.7(**) \\
\hline
a P-value & & 0.0076 \\
\hline
unadjustedb OR, & & 0.92** \\
\hline
adjustedb,c OR, & & 0.98 \\
\hline
\end{tabular}
\end{table}
|
PMC2889893_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\multicolumn{2}{c|}{\textbf{DAC CRS Code}} & \textbf{Imputed Percentages} \\
\hline
\textbf{12110} & \textbf{Health policy and administrative management} & \textbf{40\%} \\
\hline
12181 & Medical education/training & \textbf{40\%} \\
\hline
12191 & Medical services & \textbf{40\%} \\
\hline
12220 & Basic health care & \textbf{40\%} \\
\hline
12230 & Basic health infrastructure & \textbf{40\%} \\
\hline
12240 & Basic nutrition & 100\% \\
\hline
12250 & Infectious disease control & \textbf{40\%} \\
\hline
12261 & Health education & \textbf{40\%} \\
\hline
12262 & Malaria control & 88.5\% \\
\hline
12263 & Tuberculosis control & 18.5\% \\
\hline
12281 & Health personnel development & \textbf{40\%} \\
\hline
13010 & Population policy and administrative management & \textbf{40\%} \\
\hline
13020 & Reproductive health care & 100\% \\
\hline
13030 & Family planning & 100\% \\
\hline
13040 & STD control including HIV/AIDS & 46.1\% \\
\hline
13081 & Personnel development for population and reproductive health & 100\% \\
\hline
14030 & Basic drinking water supply and basic sanitation & 15\% \\
\hline
14031 & Basic drinking water supply & 15\% \\
\hline
14032 & Basic sanitation & 15\% \\
\hline
51010 & General budget support & 4\% \\
\hline
\end{tabular}
\end{table}
|
PMC3170569_table_0
|
|
\begi\textbf{\textbf{n}}{table}
\ce\textbf{\textbf{n}}teri\textbf{\textbf{n}}g
\label{tab:tablelabel}
\begi\textbf{\textbf{n}}{tabular}{|l|l|l|l|l|l|}
\hli\textbf{\textbf{n}}e
& \multicolum\textbf{\textbf{n}}{2}{c|}{\textbf{Substa\textbf{\textbf{n}}ce misuse/ me\textbf{\textbf{n}}tal ill\textbf{\textbf{n}}ess}} & \multicolum\textbf{\textbf{n}}{2}{c|}{\textbf{Others}} \\
\hli\textbf{\textbf{n}}e
& \textbf{\textbf{n}} & \textbf{\textbf{\%}} & \textbf{\textbf{n}} & \textbf{\textbf{\%}} & \textbf{p-value} \\
\hli\textbf{\textbf{n}}e
Time of day, \textbf{\textbf{n}} = 28527 & & & & & <0.001 \\
\hli\textbf{\textbf{n}}e
08.00-15.29 & 162 & 22.7 & 10381 & 37.3 \\
\hli\textbf{\textbf{n}}e
15.30-22.59 & 313 & 43.8 & 14121 & 50.8 \\
\hli\textbf{\textbf{n}}e
23.00-07.59 & 240 & 33.6 & 3310 & 11.9 \\
\hli\textbf{\textbf{n}}e
Priority grade, \textbf{\textbf{n}} = 28387 & & & & & <0.001 \\
\hli\textbf{\textbf{n}}e
Acute & 31 & 4.6 & 802 & 2.9 \\
\hli\textbf{\textbf{n}}e
Urge\textbf{\textbf{n}}t & 249 & 36.7 & 8523 & 30.8 \\
\hli\textbf{\textbf{n}}e
Not urge\textbf{\textbf{n}}t & 398 & 58.7 & 18384 & 66.3 \\
\hli\textbf{\textbf{n}}e
Actio\textbf{\textbf{n}} take\textbf{\textbf{n}}, \textbf{\textbf{n}} = 28417 & & & & & <0.001 \\
\hli\textbf{\textbf{n}}e
Co\textbf{\textbf{n}}tact with \textbf{\textbf{n}}urse \\
\hli\textbf{\textbf{n}}e
Telepho\textbf{\textbf{n}}e advice & 209 & 30.8 & 4949 & 17.8 \\
\hli\textbf{\textbf{n}}e
Co\textbf{\textbf{n}}sultatio\textbf{\textbf{n}} & 13 & 1.9 & 473 & 1.7 \\
\hli\textbf{\textbf{n}}e
Co\textbf{\textbf{n}}tact with GP \\
\hli\textbf{\textbf{n}}e
Telepho\textbf{\textbf{n}}e advice & 78 & 11.5 & 2514 & 9.1 \\
\hli\textbf{\textbf{n}}e
Co\textbf{\textbf{n}}sultatio\textbf{\textbf{n}} & 314 & 46.2 & 17481 & 63.0 \\
\hli\textbf{\textbf{n}}e
Home visit & 9 & 1.3 & 235 & 0.8 \\
\hli\textbf{\textbf{n}}e
Emerge\textbf{\textbf{n}}cy call-out & 19 & 2.8 & 499 & 1.8 \\
\hli\textbf{\textbf{n}}e
Other & 37 & 5.4 & 1587 & 5.7 \\
\hli\textbf{\textbf{n}}e
\e\textbf{\textbf{n}}d{tabular}
\e\textbf{\textbf{n}}d{table}
|
PMC3434113_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Infection type} & \textbf{Antimicrobials} & \textbf{Duration of treatment} \\
\hline
Vaginal cuff cellulitis & Oral regimen Amoxicillin/clavulanate 875/125 mg q 12 h OR Ciprofloxacin 500 mg q 12 h PLUS Metronidazole 500 mg q 12 h OR Trimethoprim/sulfamethoxazole 160/800 mg q 12 h PLUS Metronidazole 500 mg q 12 h & 7–14 days \\
\hline
Pelvic cellulitis and pelvic abscesses[a] & Parenteral regimens Clindamycin 900 mg q 8 h or Metronidazole 500 mg q 12 h PLUS Ceftriaxone 2 g q 24 h OR Clindamycin 900 mg q 8 h or Metronidazole 500 mg q 12 h PLUS Penicillin 5 million u q 6 h or Ampicillin 2 g q 6 h PLUS Gentamicin 5 mg/kg IBW q 24 h OR h[b] Aztreonam 2 g q 8 Oral regimen Metronidazole 500 mg q 12 h PLUS Trimethoprim/sulfamethoxazole 160/800 mg q 12 h OR Amoxicillin/clavulanate (875/125 mg q 12) & 14 days \\
\hline
\end{tabular}
\end{table}
|
PMC4348594_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Substances} & \textbf{Chemical nature} & \textbf{Prebiotic action} \\
\hline
Inulin (In) & Oligosaccharide & yes \\
\hline
Dextrin (Dex) & Oligosaccharide & yes* \\
\hline
Crystalean® starch (Crys) & Resistant starch & yes* \\
\hline
Glycerine (Gly) & Polyalcohol & no \\
\hline
Sorbitol (Sor) & Polyalcohol & no \\
\hline
Mannitol (Man) & Polyalcohol & no \\
\hline
\end{tabular}
\end{table}
|
PMC3257643_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Mean$\pm$SD} & \textbf{Range} \\
\hline
SCRMDQ & 7.665.8 & 0–24 \\
\hline
Rural area & 9.665.9 & 0–24 \\
\hline
Urban area & 5.865.1 & 0–24 \\
\hline
SCODI & 31.1621.6 & 0–84 \\
\hline
Rural area & 37.6623.1 & 0–84 \\
\hline
Urban area & 25.3618.4 & 0–82 \\
\hline
VAS & 42.5619.9 & 2–90 \\
\hline
Rural area & 46.1620.3 & 3–90 \\
\hline
Urban area & 39.2619.1 & 2–90 \\
\hline
\end{tabular}
\end{table}
|
PMC3267758_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Correlation with LEFS}} \\
\hline
& \multirow{2}{*}{\textbf{Hip group r (95\%-CI)}} & \multirow{2}{*}{\textbf{Knee group r (95\%-CI)}} \\
\hline
\\
\hline
HOOS/KOOS \\
\hline
Pain & 0.71 (0.60 – 0.79) & 0.65 (0.58 - 0.72) \\
\hline
Symptoms & 0.56 (0.41 – 0.67) & 0.42 (0.32 – 0.52) \\
\hline
Function, daily living & 0.78 (0.69 – 0.84) & 0.78 (0.73 – 0.83) \\
\hline
Function, sports and recreation & 0.74 (0.64 – 0.82) & 0.63 (0.55 – 0.70) \\
\hline
Quality of life & 0.72 (0.62 – 0.80) & 0.60 (0.52 – 0.67) \\
\hline
SF36 \\
\hline
Pain & 0.51 (0.35 – 0.64) & 0.66 (0.59 – 0.72) \\
\hline
Functioning & 0.82 (0.75 – 0.88) & 0.81 (0.77 – 0.85) \\
\hline
HADS \\
\hline
Anxiety & −0.25† (-0.42 – -0.07) & −0.10 (-0.22 – 0.02) \\
\hline
Depression & −0.30† (-0.46 – -0.12) & −0.28 (-0.38 – -0.16) \\
\hline
CIS & −0.55† (-0.67 – -0.41) & −0.47 (-0.56 – -0.37) \\
\hline
\end{tabular}
\end{table}
|
PMC3406936_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
F2 Refinement on & Primary atom site location: structure-invariant direct methods \\
\hline
Least-squares matrix: full & Secondary atom site location: difference Fourier map \\
\hline
R[F2 2σ(F2)] > = 0.060 & Hydrogen site location: inferred from neighbouring sites \\
\hline
wR(F2) = 0.176 & H-atom parameters constrained \\
\hline
S = 1.03 & 1/[σ2(Fo 2) (0.0773P)2 w = + + 1.8092P] 2 2)/3 where P = (Fo + 2Fc \\
\hline
2336 reflections & (Δ/σ)max < 0.001 \\
\hline
156 parameters & Å−3 Δρmax = 0.40 e \\
\hline
11 restraints & Å−3 Δρmin = −0.33 e \\
\hline
\end{tabular}
\end{table}
|
PMC3007321_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Spouse of the household head}} & \multicolumn{3}{c|}{\textbf{Children of the household head}} \\
\hline
& \textbf{\textbf{Nuclear Household}} & \textbf{\textbf{Extended Household}} & \textbf{\textbf{Total}} & \textbf{\textbf{Nuclear Household}} & \textbf{\textbf{Extended Household}} & \textbf{\textbf{Total}} \\
\hline
Without education & 0.00** & 0.01** & 0.01 & 0.05*** & 0.03*** & 0.05 \\
\hline
Primary education & 0.55*** & 0.71*** & 0.6 & 0.68*** & 0.63*** & 0.67 \\
\hline
Secondary education & 0.36*** & 0.24*** & 0.33 & 0.22*** & 0.28*** & 0.23 \\
\hline
University education & 0.08*** & 0.04*** & 0.07 & 0.05 & 0.05 & 0.05 \\
\hline
Age & 43.71*** & 48.85*** & 45.13 & 14.49*** & 20.50*** & 16.13 \\
\hline
Has health insurance & 0.43* & 0.45* & 0.43 & 0.33*** & 0.30*** & 0.32 \\
\hline
\end{tabular}
\end{table}
|
PMC3292947_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Annual FIT scheme} & \textbf{Colonoscopy scheme} \\
\hline
Enrollment & 5,863 & 4,869 \\
\hline
Colonoscopy findings \\
\hline
Adenoma & 93 (1.6\%) & 1,151 (23.6\%) \\
\hline
Advanced neoplasia & 56 (1.0\%) & 188 (3.9\%) \\
\hline
CRC & 10 (0.2\%) & 14 (0.3\%) \\
\hline
\end{tabular}
\end{table}
|
PMC4559662_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{\textbf{Parameter}} & \textbf{\textbf{Value}} & \textbf{\textbf{Parameter}} & \textbf{\textbf{Value}} \\
\hline
γ act & a0.0083/s & δ mRNA & a0.0029/s \\
\hline
γ unact & c0.00075/s & NDNA & b3.3 \\
\hline
\multirow{2}{*}{γ CI v} & ab0.0158/s & μ & b0.00044/s \\
\hline
b2um3 & Nns & b4.64× 106 \\
\hline
\end{tabular}
\end{table}
|
PMC4557085_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{5}{c|}{\textbf{No. genes (filtering + imputation)}} & \multicolumn{5}{c|}{\textbf{No. MV (filtering + imputation)}} \\
\hline
\textbf{Datasets} & \textbf{\textbf{BPCA}} & \textbf{\textbf{KNN}} & \textbf{LSS} & \textbf{\textbf{Mean}} & \textbf{\textbf{Median}} & \textbf{\textbf{BPCA}} & \textbf{\textbf{KNN}} & \textbf{LLS} & \textbf{\textbf{Mean}} & \textbf{\textbf{Median}} \\
\hline
alizadeh-2000-v1 & 960 & 945 & 962 & 932 & 932 & 1.96 & 1.91 & 1.97 & 1.83 & 1.83 \\
\hline
alizadeh-2000-v2 & 1075 & 1050 & 1081 & 1030 & 1030 & 2.71 & 2.63 & 2.72 & 2.59 & 2.59 \\
\hline
alizadeh-2000-v3 & 1075 & 1050 & 1081 & 1030 & 1030 & 2.71 & 2.63 & 2.72 & 2.59 & 2.59 \\
\hline
bredel-2005 & 3819 & 3833 & 3825 & 3850 & 3852 & 0.81 & 0.82 & 0.81 & 0.84 & 0.84 \\
\hline
chen-2002 & 2240 & 2246 & 2238 & 2329 & 2340 & 2.25 & 2.24 & 2.23 & 2.31 & 2.32 \\
\hline
garber-2001 & 2563 & 2540 & 2578 & 2584 & 2603 & 1.94 & 1.92 & 1.95 & 1.95 & 1.95 \\
\hline
lapointe-2004-v1 & 4161 & 4159 & 4170 & 4196 & 4292 & 1.94 & 1.92 & 1.95 & 1.95 & 1.95 \\
\hline
lapointe-2004-v2 & 3846 & 3811 & 3833 & 3838 & 3930 & 2.50 & 2.50 & 2.50 & 2.53 & 2.58 \\
\hline
liang-2005 & 2531 & 2528 & 2529 & 2519 & 2521 & 2.32 & 2.29 & 2.31 & 2.33 & 2.37 \\
\hline
risinger-2003 & 942 & 2074 & 2078 & 2073 & 2073 & 0.84 & 0.83 & 0.84 & 0.81 & 0.81 \\
\hline
tomlins-2006 & 2027 & 2020 & 2039 & 2018 & 2018 & 2.41 & 2.40 & 2.43 & 2.40 & 2.40 \\
\hline
tomlins-2006-v2 & 2118 & 2118 & 2124 & 2103 & 2103 & 2.37 & 2.34 & 2.37 & 2.34 & 2.34 \\
\hline
\textbf{\textbf{Mean}} & 2294 & 945 & 2378 & 2375 & 2018 & 2.06 & 2.04 & 2.07 & 2.04 & 2.05 \\
\hline
\end{tabular}
\end{table}
|
PMC4350881_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Parameter} & \textbf{Description} & \textbf{Value} \\
\hline
β & Learning rate & 0.15 \\
\hline
λ & Tag/Trace decay rate & 0.20 \\
\hline
γ & Discount factor & 0.90 \\
\hline
α & Tag persistence & 1-λγ \\
\hline
ε & Exploration rate & 0.025 \\
\hline
\end{tabular}
\end{table}
|
PMC4351255_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Globins} & \textbf{Possible bacterial ancestor} \\
\hline
Saccharomycete group 2a FHbs & Bacilli (Firmicutes), Proteobacteria, Planctomycetes \\
\hline
Saccharomycete group 2b FHbs & Proteobacteria, Chlamydia/Verrumicrobia \\
\hline
Basidiomycota, Pucciniomycotina FHb & Actinomycetes (Actinobacteria) \\
\hline
Fungi, Rotifer, Heterolobosan Sgbs & Planctomycetes, Proteobacteria \\
\hline
Blastocladiomycota T1 gb & Cyanobacteria, Proteobacteria \\
\hline
Chytridiomycota, Chlorophyte T1 gbs & Cyanobacteria, Proteobacteria \\
\hline
\end{tabular}
\end{table}
|
PMC3287990_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multirow{3}{*}{\textbf{Uninfected n = 29 n (\%)}} & \multirow{3}{*}{\textbf{Latent TB n = 21 n (\%)}} & \multirow{3}{*}{\textbf{Probable TB disease n = 20 n (\%)}} & \multirow{3}{*}{\textbf{Definite TB disease n = 5 n (\%)}} \\
\hline
\\
\hline
\\
\hline
Age, months (median and IQR) & 77 (28–101) & 86 (61–101) & 52(27–82) & 47 (8–97) \\
\hline
Immigrated & 21 (72.4) & 15 (71.4) & 18 (90) & 4 (80.0) \\
\hline
BCG vaccinated & 5 (17.2) & 7 (33.3) & 1 (5.0) & 0 (0.0) \\
\hline
TST (mm) \\
\hline
,5 & 28 (96.5) & 0 (0.0) & 0 (0.0) & 1 (20.0) \\
\hline
$5 and ,10 & 1 (3.5) & 1 (4.8) & 2 (10.0) & 0 (0.0) \\
\hline
$10 ,15 and & 0 (0.0) & 5 (23.1) & 1 (5.0) & 1 (20.0) \\
\hline
$15 & 0 (0.0) & 15 (71.5) & 17 (85.0) & 3 (60.0) \\
\hline
QFT-G-IT result \\
\hline
negative & 29 (100.0) & 5 (23.1) & 3 (15.0) & 5 (100.0) \\
\hline
positive & 0 (0.0) & 15 (71.5) & 17 (85.0) & 0 (0.0) \\
\hline
indeterminate & 0 (0.0) & 1 (4.8) & 0 (0.0) & 0 (0.0) \\
\hline
\end{tabular}
\end{table}
|
PMC3461005_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{x} & \textbf{y} & \textbf{z} & \textbf{Uiso*/Ueq} \\
\hline
Cd1 & 1.0000 & 0.5000 & 0.0000 & 0.01268 (6) \\
\hline
O1 & 0.79598 (18) & 0.30467 (18) & 0.37932 (11) & 0.0144 (2) \\
\hline
O1W & 1.00099 (19) & 0.79679 (19) & 0.10974 (11) & 0.0163 (2) \\
\hline
H1WA & 0.8758 & 0.7921 & 0.0875 & 0.024* \\
\hline
H1WB & 1.1256 & 0.8837 & 0.0939 & 0.024* \\
\hline
O2 & 0.93465 (18) & 0.33456 (19) & 0.19160 (11) & 0.0165 (2) \\
\hline
O3 & 0.64486 (18) & 0.35849 (19) & −0.01845 (11) & 0.0161 (2) \\
\hline
O4 & 0.31702 (18) & 0.12595 (19) & 0.01275 (11) & 0.0164 (2) \\
\hline
C1 & 0.6758 (3) & 0.2758 (3) & 0.59042 (16) & 0.0170 (3) \\
\hline
H1A & 0.8180 & 0.2975 & 0.6218 & 0.020* \\
\hline
C2 & 0.5088 (3) & 0.2453 (3) & 0.67327 (16) & 0.0186 (3) \\
\hline
H2A & 0.5371 & 0.2462 & 0.7627 & 0.022* \\
\hline
C3 & 0.2996 (3) & 0.2132 (3) & 0.62646 (16) & 0.0192 (3) \\
\hline
H3A & 0.1869 & 0.1917 & 0.6841 & 0.023* \\
\hline
C4 & 0.2562 (3) & 0.2127 (3) & 0.49686 (16) & 0.0162 (3) \\
\hline
H4A & 0.1144 & 0.1926 & 0.4657 & 0.019* \\
\hline
C5 & 0.4221 (3) & 0.2421 (2) & 0.41095 (15) & 0.0137 (3) \\
\hline
C6 & 0.6282 (3) & 0.2734 (2) & 0.46024 (15) & 0.0138 (3) \\
\hline
C7 & 0.3889 (3) & 0.2351 (2) & 0.27516 (15) & 0.0131 (3) \\
\hline
H7A & 0.2487 & 0.2123 & 0.2398 & 0.016* \\
\hline
C8 & 0.5526 (3) & 0.2604 (2) & 0.19545 (15) & 0.0123 (3) \\
\hline
C9 & 0.7689 (3) & 0.3026 (2) & 0.24937 (15) & 0.0127 (3) \\
\hline
C10 & 0.5040 (3) & 0.2474 (2) & 0.05228 (15) & 0.0127 (3) \\
\hline
\end{tabular}
\end{table}
|
PMC3050216_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{\textbf{Compound}} & \textbf{\textbf{Amount, − 1 g kg dry weight}} & \textbf{\textbf{Compound}} & \textbf{\textbf{Amount, − 1 g kg dry weight}} \\
\hline
Protein & 243.056 & Iodine & 0.003 \\
\hline
Fat & 44.444 & Copper & 0.018 \\
\hline
Fiber & 88.889 & Iron & 0.207 \\
\hline
Calcium & 12.847 & Sulfur & 2.222 \\
\hline
Phosphorus & 9.486 & Zink & 0.107 \\
\hline
Sodium & 2.806 & Cobalt & 0.002 \\
\hline
Starch & 458.333 & Selenium & 0.005 \\
\hline
Lysine & 12.528 & Vitamin A & 12 000 units \\
\hline
Methionine & 3.750 & Vitamin D3 & 800 units \\
\hline
Methionone+Cysteine & 8.611 & Vitamin E & 0.108 \\
\hline
Tryptophan & 3.333 & Vitamin K3 & 0.003 \\
\hline
Threonine & 8.861 & Vitamin B1 & 0.014 \\
\hline
Arginine & 15.278 & Vitamin B2 & 0.008 \\
\hline
Histidine & 6.236 & Vitamin B6 & 0.017 \\
\hline
Leucine & 17.500 & Vitamin B12 & 0.000 \\
\hline
Isoleucine & 9.931 & Biotin & 0.001 \\
\hline
Valine & 11.931 & Folic acid & 0.003 \\
\hline
Phenilalanine+Thyrosine & 19.167 & Nicotinic acid & 0.157 \\
\hline
Magnesium & 3.972 & Pantothenic acid & 0.036 \\
\hline
Potassium & 13.250 & Choline & 2.747 \\
\hline
Manganese & 0.104 & Linoleic acid & 0.013 \\
\hline
\end{tabular}
\end{table}
|
PMC4491854_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Etiology} & \textbf{Examples} \\
\hline
Intra abdominal catastrophe & Intestinal ischaemia, perforation or obstruction \\
\hline
Mucosal disruption & Peptic ulcer disease, inflammatory bowel disease \\
\hline
Infections \\
\hline
Pulmonary disorders & Chronic obstructive pulmonary disease, asthma, mechanical ventilation \\
\hline
Iatrogenic & Endoscopy \\
\hline
Reduced intestinal motility & Diabetes, pseudo obstruction \\
\hline
Immunological compromise & Steroids, chemotherapy \\
\hline
\end{tabular}
\end{table}
|
PMC3601500_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Bruker SMART APEX CCD diffractometer & 4760 independent reflections \\
\hline
Radiation source: sealed tube & 3490 reflections with I > 2σ(I) \\
\hline
graphite & Rint = 0.067 \\
\hline
phi and ω scans & θmax = 26.0°, θmin = 1.6° \\
\hline
Absorption correction: multi-scan (SADABS; Bruker, 2002) & h = −14→15 \\
\hline
Tmin = 0.46, Tmax = 0.55 & k = −22→22 \\
\hline
18891 measured reflections & l = −13→12 \\
\hline
\end{tabular}
\end{table}
|
PMC3007586_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Number (\%) of patients}} \\
\hline
& \textbf{$\leq$65 Age years N = 598} & \textbf{Age >65 years N = 180} & \textbf{Overall N = 778} \\
\hline
OaDa Discontinued tadalafil & 61 (100.0) & 46 (100.0) & 107 (100.0) \\
\hline
Reasons \\
\hline
Lack of efficacy (hardness of erection) & 17 (27.9) & 16 (34.4) & 33 (30.8) \\
\hline
Adverse event & 10 (22.5) & 12 (26.1) & 22 (20.6) \\
\hline
Cost of medication & 11 (18.0) & 5 (10.9) & 16 (15.0) \\
\hline
Didn’t want to take a pill every day & 7 (11.0) & 5 (10.9) & 12 (11.2) \\
\hline
Patient discontinued study & 7 (11.5) & 2 (4.3) & 9 (8.4) \\
\hline
Partner’s request & 2 (3.3) & 3 (6.5) & 5 (4.7) \\
\hline
Felt that medication controlled his sexual life & 2 (4.2) & 1 (2.2) & 3 (2.8) \\
\hline
Slow onset of action & 2 (3.3) & 1 (2.2) & 3 (2.8) \\
\hline
Lack of efficacy (duration of erection) & 1 (1.6) & 1 (2.2) & 2 (1.9) \\
\hline
Lack of confidence in medication & 1 (1.6) & 0 & 1 (0.9) \\
\hline
Non-desired spontaneous erections & 1 (1.6) & 0 & 1 (0.9) \\
\hline
\end{tabular}
\end{table}
|
PMC4643510_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{x} & \textbf{y} & \textbf{z} & \textbf{Uiso*/Ueq} \\
\hline
C1 & 0.4107 (3) & 0.83139 (18) & −0.04103 (18) & 0.0431 (5) \\
\hline
C2 & 0.2717 (3) & 0.9110 (2) & −0.0806 (2) & 0.0609 (7) \\
\hline
H2 & 0.2077 & 0.9271 & −0.1485 & 0.073* \\
\hline
C3 & 0.4597 (4) & 0.8595 (2) & 0.1155 (2) & 0.0560 (6) \\
\hline
H3 & 0.5236 & 0.8417 & 0.1831 & 0.067* \\
\hline
C4 & 0.3238 (4) & 0.9395 (2) & 0.0809 (3) & 0.0687 (8) \\
\hline
H4 & 0.2964 & 0.9752 & 0.1243 & 0.082* \\
\hline
C5 & 0.2299 (4) & 0.9658 (2) & −0.0178 (3) & 0.0698 (8) \\
\hline
H5 & 0.1384 & 1.0203 & −0.0425 & 0.084* \\
\hline
C6 & 0.4609 (3) & 0.7685 (2) & −0.10595 (18) & 0.0503 (6) \\
\hline
H6A & 0.3458 & 0.7537 & −0.1702 & 0.060* \\
\hline
H6B & 0.5515 & 0.8079 & −0.1171 & 0.060* \\
\hline
C7 & 0.6087 (3) & 0.59950 (19) & −0.09923 (16) & 0.0460 (5) \\
\hline
H7A & 0.6875 & 0.6357 & −0.1205 & 0.055* \\
\hline
H7B & 0.4990 & 0.5673 & −0.1575 & 0.055* \\
\hline
C8 & 0.7246 (3) & 0.51540 (18) & −0.02358 (16) & 0.0397 (5) \\
\hline
C9 & 0.7807 (3) & 0.4226 (2) & −0.05024 (19) & 0.0495 (6) \\
\hline
H9 & 0.7444 & 0.4107 & −0.1165 & 0.059* \\
\hline
C10 & 0.8902 (4) & 0.3486 (2) & 0.0219 (2) & 0.0537 (6) \\
\hline
H10 & 0.9305 & 0.2863 & 0.0054 & 0.064* \\
\hline
C11 & 0.9394 (3) & 0.36760 (19) & 0.1189 (2) & 0.0508 (6) \\
\hline
H11 & 1.0125 & 0.3182 & 0.1690 & 0.061* \\
\hline
C12 & 0.8788 (3) & 0.46096 (18) & 0.14068 (18) & 0.0456 (5) \\
\hline
H12 & 0.9123 & 0.4736 & 0.2064 & 0.055* \\
\hline
Cl1 & 0.71768 (8) & 0.63978 (5) & 0.25220 (4) & 0.04925 (16) \\
\hline
Cl2 & 0.98849 (8) & 0.77735 (5) & 0.14453 (5) & 0.05218 (16) \\
\hline
N1 & 0.5035 (3) & 0.80611 (14) & 0.05554 (14) & 0.0426 (4) \\
\hline
N2 & 0.7730 (2) & 0.53478 (14) & 0.07069 (13) & 0.0386 (4) \\
\hline
O1 & 0.5448 (3) & 0.67253 (13) & −0.05431 (12) & 0.0539 (4) \\
\hline
Zn1 & 0.71979 (3) & 0.686250 (19) & 0.111610 (17) & 0.03705 (11) \\
\hline
\end{tabular}
\end{table}
|
PMC2959519_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
Cl1 & 0.0657 (4) & 0.0623 (3) & 0.0364 (3) & −0.0082 (2) & −0.0090 (2) & 0.0036 (2) \\
\hline
O1 & 0.0295 (7) & 0.0825 (10) & 0.0405 (7) & −0.0090 (6) & −0.0035 (5) & 0.0011 (7) \\
\hline
O2 & 0.0480 (8) & 0.0676 (9) & 0.0339 (7) & −0.0103 (6) & −0.0082 (6) & 0.0022 (6) \\
\hline
N1 & 0.0262 (7) & 0.0446 (8) & 0.0345 (8) & −0.0009 (6) & −0.0015 (6) & −0.0026 (6) \\
\hline
C1 & 0.0342 (9) & 0.0362 (9) & 0.0347 (9) & 0.0031 (7) & −0.0061 (7) & −0.0054 (7) \\
\hline
C2 & 0.0340 (9) & 0.0461 (10) & 0.0394 (9) & −0.0005 (7) & −0.0140 (7) & −0.0084 (8) \\
\hline
C3 & 0.0272 (8) & 0.0396 (9) & 0.0428 (10) & −0.0034 (7) & −0.0074 (7) & −0.0068 (7) \\
\hline
C4 & 0.0284 (8) & 0.0315 (8) & 0.0357 (9) & 0.0027 (6) & −0.0049 (7) & −0.0067 (6) \\
\hline
C5 & 0.0306 (8) & 0.0380 (9) & 0.0359 (9) & −0.0012 (7) & −0.0096 (7) & −0.0077 (7) \\
\hline
C6 & 0.0303 (8) & 0.0378 (9) & 0.0391 (9) & −0.0056 (7) & −0.0052 (7) & −0.0047 (7) \\
\hline
C7 & 0.0297 (9) & 0.0390 (9) & 0.0361 (9) & −0.0016 (7) & −0.0046 (7) & −0.0070 (7) \\
\hline
C9 & 0.0283 (8) & 0.0317 (8) & 0.0331 (8) & −0.0041 (6) & −0.0052 (6) & −0.0051 (6) \\
\hline
C10 & 0.0299 (9) & 0.0446 (10) & 0.0400 (9) & 0.0065 (7) & −0.0066 (7) & −0.0089 (7) \\
\hline
C11 & 0.0303 (8) & 0.0501 (10) & 0.0364 (9) & 0.0006 (7) & 0.0002 (7) & −0.0118 (8) \\
\hline
C12 & 0.0389 (9) & 0.0373 (9) & 0.0338 (9) & −0.0088 (7) & −0.0075 (7) & −0.0047 (7) \\
\hline
C13 & 0.0341 (9) & 0.0357 (9) & 0.0433 (10) & 0.0025 (7) & −0.0093 (7) & −0.0026 (7) \\
\hline
C14 & 0.0271 (8) & 0.0382 (9) & 0.0413 (9) & −0.0002 (7) & −0.0006 (7) & −0.0072 (7) \\
\hline
C15 & 0.0558 (13) & 0.0737 (14) & 0.0414 (11) & −0.0162 (11) & −0.0041 (9) & 0.0068 (10) \\
\hline
\end{tabular}
\end{table}
|
PMC3515183_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Nutrientse} & \textbf{Group A Intervention = 47 n} & \textbf{Group B Intervention = 50 n} & \textbf{Group C Control = 41 n} & \textbf{EAR 1/AI 2 RDI 3/SDT 4} & \textbf{p 5} \\
\hline
Baseline \\
\hline
Protein (g) 6 & 86 $\pm$ 17 (49–128) & 82 $\pm$ 18 (46–128) & 83.5 $\pm$ 13.6 (56–117) & 37 1/46 3 \\
\hline
Change & 2.2 $\pm$ 19 (−67–35) & 2.0 $\pm$ 17 (−34–45) & 0.10 $\pm$ 16 (−53–35) & & 0.8 \\
\hline
Fat (g) & 72 $\pm$ 16 (35–98) & 75 $\pm$ 14 (47–102) & 74 $\pm$ 17 (42–112) & N/A \\
\hline
Change & 2.30 $\pm$ 15 (−36–24) & 2 $\pm$ 19 (−49–57) & 4 $\pm$ 20 (−69–41) & & 0.9 \\
\hline
CHO (g) & 220 $\pm$ 43 (150–350) & 216 $\pm$ 32 (107–275) & 220 $\pm$ 41 (132–304) & N/A \\
\hline
Change & 19 $\pm$ 72 (−115–195) & 5.2 $\pm$ 52 (−148–133) & 6 $\pm$ 65 (−155–124) & & 0.5 \\
\hline
Fibre (g) & 27 $\pm$ 8 (14–50) & 27 $\pm$ 8 (12–56) & 28 $\pm$ 8 (13–43) & 25 2/28 4 \\
\hline
Change & 5.7 $\pm$ 6.6 (−22–7) & 6.4 $\pm$ 10.3 (−28–18) & −0.5 $\pm$ 0.0 (−24–24) & & 0.01 \\
\hline
Folate (μg) & 368 $\pm$ 153 (102–812) & 380 $\pm$ 225 (151–1646) & 381 $\pm$ 134 (205–687) & 400 3/600 4 \\
\hline
Change & 109 $\pm$ 213 (−865–447) & 121 $\pm$ 250 (−561–1177) & −9 $\pm$ 16 (−237–548) & & 0.01 \\
\hline
Sodium (mg) & 2345 $\pm$ 618 (1261–4046) & 2766 $\pm$ 900 (1242–4593) & 2551 $\pm$ 979 (947–6405) & 1600 4 \\
\hline
Change & −63 $\pm$ 887 (−2466–1566) & −376 $\pm$ 943 (−1561–2461) & 24.5 $\pm$ 1256 (−2147–3230) & & 0.2 \\
\hline
Potassium (mg) & 3695 $\pm$ 766 (2400–6261) & 3643 $\pm$ 1000 (2013–6902) & 3781 $\pm$ 790 (2410–6027) & 2800 2/4700 4 \\
\hline
Change & 935 $\pm$ 953 (−3246–775) & 1393 $\pm$ 1375 (−5401–2483) & 64 $\pm$ 933 (−1758–2414) & & 0.001 \\
\hline
Magnesium (mg) & 365 $\pm$ 930 (232–694) & 366 $\pm$ 105 (208–667) & 385 $\pm$ 112 (231–941) & 265 1/320 3 \\
\hline
Change & 73 $\pm$ 134 (−548–298) & 54 $\pm$ 106 (−285–229) & −20 $\pm$ 113 (−143–532) & & 0.001 \\
\hline
Calcium (mg) & 850 $\pm$ 257 (375–1532) & 872 $\pm$ 347 (404–2,166) & 905 $\pm$ 270 (396–1632) & 1100 1/1300 3 \\
\hline
Change & 181 $\pm$ 353 (−935–635) & 164 $\pm$ 41 (−974–1514) & 5 $\pm$ 293 (−621–679) & & 0.03 \\
\hline
\end{tabular}
\end{table}
|
PMC4425157_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{2}{c|}{\textbf{Multiple logistic regression model}} & \multicolumn{2}{c|}{\textbf{Multiple linear regression model}} \\
\hline
& \textbf{Adjusted OR (95\% CI)} & \textbf{\textbf{p-value}} & \textbf{(SE) β} & \textbf{\textbf{p-value}} \\
\hline
& 1a Model \\
\hline
Physical & b activity participation \\
\hline
Less than three times a week (ref) & ref. & & ref. \\
\hline
Equal to or more than three times a week & 0.81 (0.69–0.96) & 0.014 & -0.42 (0.12) & 0.001 \\
\hline
Social & activity participation \\
\hline
Less than once a week (ref) & ref. & & ref. \\
\hline
Equal to or more than once a week & 0.87 (0.75–1.00) & 0.047 & -0.28 (0.11) & 0.011 \\
\hline
\multicolumn{2}{c|}{Religious} \\
\hline
Less than once a week (ref) & ref. & & ref. \\
\hline
Equal to or more than once a week & 0.78 (0.67–0.90) & 0.001 & -0.34 (0.11) & 0.003 \\
\hline
& 2a Model \\
\hline
\multicolumn{2}{c|}{Group classification} \\
\hline
Group A (No frequent physical, social, and religious activity) (ref) & ref. & & ref. \\
\hline
Group B (Only one type of activity frequently) & 0.86 (0.75–0.98) & 0.020 & -0.41 (0.10) & <0.001 \\
\hline
Group C (Two types or three types of activity frequently) & 0.64 (0.52–0.79) & <0.001 & -0.70 (0.15) & <0.001 \\
\hline
\end{tabular}
\end{table}
|
PMC4501692_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Origin of samples} & \textbf{N} & \textbf{Mean CAGexp} & \textbf{Median CAGexp} & \textbf{Mean eAO} & \textbf{Median eAO} \\
\hline
Southern European & 63 & 44.36$\pm$2.82 & 43 & 43.16$\pm$11.19 & 42 \\
\hline
\textbf{N}orthern European & 190 & 44.03$\pm$2.95 & 44 & 43.07$\pm$11.24 & 42.5 \\
\hline
Total & 253 & 44.11$\pm$2.91 & 44 & 43.09$\pm$11.21 & 42 \\
\hline
P value in Southern/\textbf{N}orthern comparison & - & 0.371 & 0.290 & 0.997 & 0.991 \\
\hline
\end{tabular}
\end{table}
|
PMC4493078_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
Gd1 & 0.0412 (3) & 0.0372 (2) & 0.0343 (2) & 0.000 & 0.01310 (17) & 0.000 \\
\hline
C1 & 0.051 (4) & 0.072 (4) & 0.052 (4) & 0.006 (4) & 0.016 (3) & 0.004 (3) \\
\hline
C2 & 0.059 (5) & 0.090 (6) & 0.048 (4) & −0.007 (4) & 0.015 (3) & 0.008 (4) \\
\hline
C3 & 0.057 (5) & 0.120 (7) & 0.038 (4) & −0.027 (5) & 0.012 (3) & −0.005 (4) \\
\hline
C4 & 0.059 (4) & 0.074 (5) & 0.052 (4) & −0.019 (4) & 0.027 (3) & −0.020 (3) \\
\hline
C5 & 0.042 (4) & 0.052 (4) & 0.038 (3) & −0.012 (3) & 0.017 (3) & −0.003 (3) \\
\hline
C6 & 0.050 (4) & 0.051 (4) & 0.046 (3) & −0.008 (3) & 0.028 (3) & −0.005 (3) \\
\hline
C7 & 0.054 (4) & 0.049 (4) & 0.059 (4) & −0.006 (3) & 0.027 (3) & −0.015 (3) \\
\hline
C8 & 0.064 (4) & 0.047 (4) & 0.062 (4) & −0.010 (3) & 0.037 (3) & −0.012 (3) \\
\hline
C9 & 0.120 (7) & 0.053 (4) & 0.095 (5) & −0.001 (4) & 0.057 (5) & −0.018 (4) \\
\hline
C10 & 0.085 (6) & 0.073 (5) & 0.100 (6) & 0.021 (4) & 0.044 (5) & 0.004 (4) \\
\hline
N1 & 0.046 (3) & 0.046 (3) & 0.043 (3) & −0.002 (2) & 0.015 (2) & −0.001 (2) \\
\hline
N2 & 0.068 (4) & 0.049 (3) & 0.072 (3) & 0.002 (3) & 0.039 (3) & −0.005 (3) \\
\hline
N3 & 0.055 (4) & 0.067 (3) & 0.059 (4) & −0.016 (3) & 0.029 (3) & −0.018 (3) \\
\hline
N4 & 0.112 (9) & 0.049 (6) & 0.101 (7) & 0.000 & 0.065 (7) & 0.000 \\
\hline
O1 & 0.053 (3) & 0.047 (2) & 0.047 (2) & 0.0048 (19) & 0.014 (2) & −0.0065 (19) \\
\hline
O2 & 0.058 (3) & 0.067 (3) & 0.048 (2) & −0.004 (2) & 0.020 (2) & 0.003 (2) \\
\hline
O3 & 0.055 (3) & 0.065 (3) & 0.045 (2) & −0.002 (2) & 0.020 (2) & −0.002 (2) \\
\hline
O4 & 0.068 (4) & 0.153 (5) & 0.082 (3) & −0.023 (3) & 0.049 (3) & −0.011 (3) \\
\hline
O5 & 0.074 (3) & 0.049 (3) & 0.074 (3) & −0.007 (2) & 0.036 (3) & −0.009 (2) \\
\hline
O6 & 0.131 (7) & 0.042 (4) & 0.150 (7) & 0.000 & 0.093 (6) & 0.000 \\
\hline
O7 & 0.147 (8) & 0.135 (8) & 0.138 (7) & 0.024 (6) & 0.039 (6) & −0.033 (6) \\
\hline
C11 & 0.137 (9) & 0.136 (9) & 0.137 (8) & 0.007 (7) & 0.072 (7) & −0.005 (7) \\
\hline
C12 & 0.132 (9) & 0.117 (9) & 0.127 (8) & 0.005 (8) & 0.057 (7) & 0.001 (8) \\
\hline
O7B & 0.146 (10) & 0.157 (10) & 0.164 (10) & 0.004 (8) & 0.086 (7) & 0.008 (8) \\
\hline
C11B & 0.135 (10) & 0.140 (10) & 0.144 (10) & 0.002 (8) & 0.071 (7) & −0.011 (8) \\
\hline
C12B & 0.129 (11) & 0.137 (11) & 0.130 (10) & −0.011 (8) & 0.064 (8) & 0.006 (8) \\
\hline
\end{tabular}
\end{table}
|
PMC3238762_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
& \textbf{Data collected} \\
\hline
Demographic data & Age; sex; place of birth; place of residence; last endemic zone visited; dates of travel (relevant for native-traveler and traveler); date of arrival to non endemic zone for malaria (native and native-traveler); date of arrival to endemic zone for malaria (resident in endemic zone); intake of antimalarial chemoprophylaxis (yes/no and drug); adherence to antimalarial chemoprophylaxis (correct vs incorrect). \\
\hline
Clinical data & Presence of symptoms (yes/no); date of onset of symptoms; liver enlargement, spleen enlargement, asthenia, headache, ocular pain, arthromyalgias, vomiting, diarrhea, rash, cough, abdominal pain, jaundice, fever, seizures, hemorrhage, shock. \\
\hline
Laboratory data & (cell/mm3); Hemoglobin (g/dl); white blood cells (cell/mm3) (cell/mm3); lymphocytes ; monocytes (cell/mm3); platelets glycaemia (mg/dl); urea (mg/dl); creatinine (mg/dl); lactic deshydrogenase enzyme –LDH- (UI/ml); alanin aminotransferase enzyme -ALT- (UI/ml); total cholesterol (mg/dl). \\
\hline
\end{tabular}
\end{table}
|
PMC3502252_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
N1—H1N1···N2i & 0.848 (17) & 2.116 (17) & 2.9600 (12) & 173.0 (17) \\
\hline
C1—H1A···Cg2ii & 0.95 & 2.88 & 3.6647 (11) & 141 \\
\hline
C12—H12A···Cg1iii & 0.95 & 2.92 & 3.6143 (13) & 131 \\
\hline
C17—H17A···Cg1iv & 0.95 & 2.61 & 3.4381 (11) & 146 \\
\hline
\end{tabular}
\end{table}
|
PMC3344455_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{\textbf{\textbf{\textbf{P}}}redictors} & \multicolumn{2}{c|}{\textbf{Urban}} & \multicolumn{2}{c|}{\textbf{Semi-urban}} & \multicolumn{2}{c|}{\textbf{Rural}} \\
\hline
& \textbf{\textbf{\textbf{AOR [95\% CI]}}} & \textbf{\textbf{\textbf{P}}} & \textbf{\textbf{\textbf{AOR [95\% CI]}}} & \textbf{\textbf{\textbf{P}}} & \textbf{\textbf{\textbf{AOR [95\% CI]}}} & \textbf{\textbf{\textbf{P}}} \\
\hline
Sex \\
\hline
Male & 1.00 \\
\hline
Female & 1.45[1.10, 1.92] & 0.009 & 1.55[1.17, 2.06] & 0.002 & 1.58[1.19, 2.10] & 0.001 \\
\hline
Educational status of adolescents \\
\hline
\textbf{\textbf{\textbf{P}}}rimary (grade 0-8) & 1.00 & & 1.00 \\
\hline
Secondary and above (grade >9) & 0.47[0.29, 0.75] & 0.002 & 0.73[0.44, 1.18] & 0.198 & 0.94[0.56, 1.58] & 0.818 \\
\hline
Household income (tertiles) \\
\hline
Low & 1.69[1.15, 2.50] & 0.008 & 1.15[0.78, 1.71] & 0.477 & 1.22[0.93, 2.81] & 0.090 \\
\hline
Middle & 1.80[1.23, 2.63] & 0.003 & 1.34[0.91, 1.96] & 0.140 & 0.70[0.39, 1.26] & 0.236 \\
\hline
High & 1.00 & & 1.00 & & 1.00 \\
\hline
Dependency ratio (tertiles) \\
\hline
Low & 1.00 & & 1.00 & & 1.00 \\
\hline
Middle & 1.08[0.75, 1.56] & 0.689 & 1.06[0.73, 1.54] & 0.772 & 1.17[0.80, 1.72] & 0.413 \\
\hline
High & 1.48[1.02, 2.14] & 0.039 & 1.49[1.02, 2.17] & 0.038 & 1.48[1.01, 2.17] & 0.047 \\
\hline
Sex of the household head \\
\hline
Male & 1.00 & & 1.00 & & 1.00 \\
\hline
Female & 1.14[0.80, 1.61] & 0.466 & 1.43[1.00, 2.05] & 0.053 & 1.95[1.35, 2.83] & <0.001 \\
\hline
Household food security at baseline \\
\hline
Food insecure & 1.00 & & 1.00 & & 1.00 \\
\hline
Food Secure & 2.59[1.95, 3.45] & <0.001 & 2.71[2.03, 3.61] & <0.001 & 2.43[1.82, 3.24] & <0.001 \\
\hline
\end{tabular}
\end{table}
|
PMC3439274_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
F2 Refinement on & Hydrogen site location: inferred from neighbouring sites \\
\hline
Least-squares matrix: full & H-atom parameters constrained \\
\hline
R[F2 2σ(F2)] > = 0.062 & 1/[σ2(Fo 2) (0.1124P)2] w = + 2 2)/3 where P = (Fo + 2Fc \\
\hline
wR(F2) = 0.188 & (Δ/σ)max < 0.001 \\
\hline
S = 1.02 & Å−3 Δρmax = 0.31 e \\
\hline
4891 reflections & Å−3 Δρmin = −0.31 e \\
\hline
518 parameters & Extinction correction: SHELXL, Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4 \\
\hline
1347 restraints & Extinction coefficient: 0.012 (4) \\
\hline
Primary atom site location: structure-invariant direct methods & Absolute structure: Flack (1983) 794 Friedel pairs \\
\hline
Secondary atom site location: difference Fourier map & Flack parameter: 0.19 (12) \\
\hline
\end{tabular}
\end{table}
|
PMC2977794_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{c|}{\textbf{Partial pension}} & \multicolumn{2}{c|}{\textbf{Full pension}} & \multicolumn{2}{c|}{\textbf{All pensions}} \\
\hline
& \textbf{(n)} & \textbf{\textbf{\textbf{(no of cases)}}} & \textbf{\textbf{\textbf{\%}}} & \textbf{\textbf{\textbf{(no of cases)}}} & \textbf{\textbf{\textbf{\%}}} & \textbf{\textbf{\textbf{(no of cases)}}} & \textbf{\textbf{\textbf{\%}}} \\
\hline
Men \\
\hline
Partial sick leave & (283) & (27) & 9.5 & (28) & 9.9 & (55) & 19.4 \\
\hline
Full sick leave & (12 817) & (319) & 2.5 & (3 060) & 23.9 & (3 379) & 26.4 \\
\hline
Women \\
\hline
Partial sick leave & (748) & (94) & 12.6 & (53) & 7.1 & (147) & 19.7 \\
\hline
Full sick leave & (15 092) & (688) & 4.6 & (3 448) & 22.8 & (4 136) & 27.4 \\
\hline
All \\
\hline
Partial sick leave & (1 031) & (121) & 11.7 & (81) & 7.9 & (202) & 19.6 \\
\hline
Full sick leave & (27 909) & (1 007) & 3.6 & (6 508) & 23.3 & (7 515) & 26.9 \\
\hline
\end{tabular}
\end{table}
|
PMC2912806_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Compound} & \textbf{F.W.} & \textbf{Solubility (μM)} & \textbf{(10-6 Permeation cm/s)} & \textbf{Retention (\%)} & \textbf{Mouse Metabolic Stability t1/2 (hr)} & \textbf{Clint (mL/min/Kg)} \\
\hline
\textbf{Compound} 1 & 471.6 & 0.50 $\pm$ 0.40 & 1057 $\pm$ 69 & 70 $\pm$ 2.0 & 0.27 $\pm$ 0 & 213 \\
\hline
\textbf{Compound} 10 & 381.5 & 0.40 $\pm$ 0 & 534 $\pm$ 25 & 80 $\pm$ 12 & 0.13 $\pm$ 0 & 438 \\
\hline
\textbf{Compound} 12 & 406.5 & 0 0 $\pm$ & 570 ND $\pm$ & 93 3.8 $\pm$ & 0.32 0 $\pm$ & 178 \\
\hline
\textbf{Compound} 13 & 406.5 & 0.90 1.2 $\pm$ & 582 205 $\pm$ & 93 0.5 $\pm$ & 0.080 0 $\pm$ & 680 \\
\hline
Albendazole & 265.3 & 5.9 $\pm$ 2.3 & 286 $\pm$ ND & 59 $\pm$ 27 & ND & ND \\
\hline
Carbamazepine & 236.3 & 87 $\pm$ 1.2 & 85 $\pm$ 21 & 43 $\pm$ 3.0 & ND & ND \\
\hline
Ranitidine HCl & 350.9 & 84 $\pm$ 1.2 & 0 $\pm$ 0 & 1.7 $\pm$ 1.3 & ND & ND \\
\hline
Verapamil HCl & 491.1 & 77 3.2 $\pm$ & 1053 ND $\pm$ & 74 7.8 $\pm$ & 0.86 0.10 $\pm$ & 67 \\
\hline
\end{tabular}
\end{table}
|
PMC4404333_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Patient} & \textbf{Age} & \textbf{Gender} & \textbf{Disease stage} & \textbf{RT Dose} & \textbf{PTV Volume} & \multicolumn{2}{c|}{\textbf{Fields}} \\
\hline
& & & & & \textbf{(cm3)} & \textbf{3D-CRT} & \textbf{IMRT} \\
\hline
1 & 21 & F & IIB Bulky & 30 Gy & 831 & 2 & 5 \\
\hline
2 & 21 & F & IIA & 30 Gy & 323 & 4 & 5 \\
\hline
3 & 53 & F & IIA & 30 Gy & 553 & 5 & 5 \\
\hline
4 & 43 & M & IIA & 30 Gy & 841 & 5 & 5 \\
\hline
5 & 13 & M & IIA & 30 Gy & 231 & 2 & 5 \\
\hline
6 & 28 & M & IIA & 30 Gy & 684 & 6 & 5 \\
\hline
7 & 33 & F & IIA & 30 Gy & 260 & 4 & 5 \\
\hline
8 & 17 & M & IIB & 30 Gy & 349 & 6 & 5 \\
\hline
9 & 34 & F & IIA & 30 Gy & 497 & 2 & 5 \\
\hline
10 & 38 & M & IIB Bulky & 30 Gy & 642 & 2 & 5 \\
\hline
\end{tabular}
\end{table}
|
PMC3484070_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
[Zn(C14H8N2O4)(H2O)2] & F000 = 752 \\
\hline
Mr = 369.63 & m−3 Dx = 1.825 Mg \\
\hline
Monoclinic, C2/c & Mo Kα radiation λ = 0.71073 Å \\
\hline
Hall symbol: -C 2yc & Cell parameters from 1194 reflections \\
\hline
a = 22.392 (5) Å & θ = 3.3–27.5º \\
\hline
b = 4.9308 (10) Å & mm−1 µ = 1.86 \\
\hline
c = 12.185 (2) Å & T = 293 K \\
\hline
β = 90.30 (3)º & Needle, orange \\
\hline
Å3 V = 1345.3 (5) & 0.14 × 0.09 × 0.08 mm \\
\hline
Z = 4 \\
\hline
\end{tabular}
\end{table}
|
PMC2977570_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{MAP} & \textbf{Aspect} & \textbf{Passage} & \textbf{Passage}2 & \textbf{Document} \\
\hline
NLMinter & 0.2631 & 0.0968 & 0.1148 & 0.3286 \\
\hline
MuMshFd & 0.2068 & 0.0840 & 0.0895 & 0.2906 \\
\hline
Okapi07 & 0.1428 & 0.0633 & 0.0641 & 0.2025 \\
\hline
Okapi06a & 0.2176 & 0.0362 & 0.0450 & 0.3476 \\
\hline
Okapi06b & 0.3147 & 0.1559 & 0.0968 & 0.4705 \\
\hline
Okapi06c & 0.2596 & 0.0759 & 0.0601 & 0.4388 \\
\hline
\end{tabular}
\end{table}
|
PMC3226257_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multirow{2}{*}{\textbf{FGF23-Quartile 1 (n = 47; FGF23, 11–40)}} & \multirow{2}{*}{\textbf{FGF23-Quartile 2 (n = 50; FGF23, 41–63)}} & \multirow{2}{*}{\textbf{FGF23-Quartile 3 (n = 49; FGF23, 64–103)}} & \multirow{2}{*}{\textbf{FGF23-Quartile 4 (n = 49; FG23, 105–2010)}} & \multirow{2}{*}{\textbf{p values}} \\
\hline
\\
\hline
Age (years) & 67.7 $\pm$ 14.2 & 68.5 $\pm$ 10.6 & 68.2 $\pm$ 10.3 & 70.5 $\pm$ 10.0 & 0.65 \\
\hline
Male & 26 (55) & 33 (66) & 35 (71) & 35 (71) & 0.31 \\
\hline
Hypertension & 38 (81) & 37 (74) & 48 (98) & 48 (98) & <0.01 \\
\hline
Diabetes mellitus & 20 (43) & 20 (40) & 29 (59) & 23 (47) & 0.23 \\
\hline
Smoking & 23 (49) & 29 (58) & 30 (61) & 28 (57) & 0.66 \\
\hline
Dyslipidemia & 35 (74) & 33 (66) & 35 (71) & 43 (88) & 0.06 \\
\hline
(kg/m2) Body mass index & 22.2 $\pm$ 2.5 & 22.4 $\pm$ 5.7 & 22.7 $\pm$ 5.4 & 22.7 $\pm$ 3.5 & 0.95 \\
\hline
Proteinuria (g/day) & 1.2 (0.1-3.3) & 0.7 (0.1-2.6) & 2.2 (0.4-4.0) & 1.2 (0.4-3.6) & 0.14 \\
\hline
C-reactive protein (mg/dL) & 0.05 (0.02-0.12) & 0.09 (0.03-0.22) & 0.13 (0.05-0.26) & 0.09 (0.05-0.35)* & 0.01 \\
\hline
Hemoglobin (g/dL) & 11.5 $\pm$ 2.2 & 11.1 $\pm$ 2.1 & 10.6 $\pm$ 2.0 & 9.6 $\pm$ 1.7** & <0.01 \\
\hline
Serum corrected calcium (mg/dL) & 9.5 $\pm$ 0.6 & 9.4 $\pm$ 0.5 & 9.5 $\pm$ 0.5 & 9.3 $\pm$ 0.6 & 0.19 \\
\hline
Serum phosphorus (mg/dL) & 3.4 $\pm$ 0.5 & 3.5 $\pm$ 0.6 & 3.6 $\pm$ 0.5 & 4.4 $\pm$ 0.9** & <0.01 \\
\hline
(mg2/dL2) Ca-P product & 32.5 $\pm$ 5.6 & 33.3 $\pm$ 6.0 & 34.4 $\pm$ 4.2 & 40.7 $\pm$ 8.5** & <0.01 \\
\hline
(ml/min/1.73m2) eGFR & 46.9 (27.0-68.9) & 33.6 (17.3-57.9) & 22.0 (16.0-35.0)** & 12.7 (9.0-17.2)** & <0.01 \\
\hline
CAAC & 23 (49) & 29 (58) & 37 (76) & 39 (80) & <0.01 \\
\hline
\end{tabular}
\end{table}
|
PMC3554512_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
F2 Refinement on & Secondary atom site location: difference Fourier map \\
\hline
Least-squares matrix: full & Hydrogen site location: inferred from neighbouring sites \\
\hline
R[F2 2σ(F2)] > = 0.065 & H-atom parameters constrained \\
\hline
wR(F2) = 0.189 & 1/[σ2(Fo 2) (0.1171P)2 w = + + 0.2599P] 2 2)/3 where P = (Fo + 2Fc \\
\hline
S = 1.07 & (Δ/σ)max = 0.001 \\
\hline
7993 reflections & Å−3 Δρmax = 0.64 e \\
\hline
470 parameters & Å−3 Δρmin = −0.69 e \\
\hline
0 restraints & Extinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4 \\
\hline
Primary atom site location: structure-invariant direct methods & Extinction coefficient: 0.038 (2) \\
\hline
\end{tabular}
\end{table}
|
PMC2979387_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
C1 & 0.114 (7) & 0.077 (6) & 0.133 (10) & −0.045 (5) & 0.000 & 0.000 \\
\hline
C2 & 0.148 (11) & 0.073 (6) & 0.168 (13) & 0.009 (6) & 0.000 & 0.000 \\
\hline
N1 & 0.116 (6) & 0.098 (5) & 0.106 (6) & −0.056 (5) & 0.000 & 0.000 \\
\hline
N11 & 0.0380 (13) & 0.0362 (13) & 0.0512 (14) & −0.0033 (10) & 0.0115 (11) & −0.0055 (11) \\
\hline
C11 & 0.052 (15) & 0.038 (10) & 0.044 (7) & −0.010 (8) & 0.007 (7) & −0.014 (7) \\
\hline
C11' & 0.033 (5) & 0.044 (11) & 0.056 (13) & −0.003 (6) & 0.010 (7) & −0.010 (7) \\
\hline
C12' & 0.038 (3) & 0.066 (5) & 0.058 (4) & 0.000 (3) & 0.001 (3) & −0.015 (4) \\
\hline
C13' & 0.061 (4) & 0.108 (7) & 0.042 (4) & 0.002 (5) & 0.002 (3) & −0.020 (4) \\
\hline
C14' & 0.072 (6) & 0.079 (6) & 0.092 (8) & −0.014 (5) & 0.003 (5) & −0.019 (6) \\
\hline
C15' & 0.098 (9) & 0.125 (11) & 0.125 (10) & −0.022 (9) & −0.025 (8) & −0.055 (10) \\
\hline
C16 & 0.0473 (17) & 0.0529 (18) & 0.0400 (15) & −0.0156 (15) & 0.0093 (14) & −0.0128 (14) \\
\hline
O16 & 0.0527 (13) & 0.0491 (13) & 0.0558 (14) & −0.0133 (11) & 0.0054 (11) & 0.0011 (11) \\
\hline
N21 & 0.0476 (15) & 0.0455 (15) & 0.0582 (16) & −0.0079 (12) & 0.0158 (13) & −0.0106 (14) \\
\hline
C21 & 0.0416 (16) & 0.0538 (18) & 0.0493 (19) & −0.0067 (14) & 0.0093 (13) & −0.0060 (15) \\
\hline
C22 & 0.0501 (18) & 0.074 (2) & 0.0449 (18) & −0.0171 (19) & 0.0121 (15) & −0.0031 (17) \\
\hline
O22 & 0.0568 (15) & 0.0703 (18) & 0.0714 (18) & −0.0174 (14) & 0.0051 (13) & 0.0133 (15) \\
\hline
C23 & 0.084 (3) & 0.112 (4) & 0.048 (2) & −0.028 (3) & 0.016 (2) & −0.011 (3) \\
\hline
C24 & 0.0427 (16) & 0.0491 (17) & 0.0461 (17) & −0.0031 (14) & 0.0028 (13) & 0.0028 (14) \\
\hline
O24 & 0.0681 (16) & 0.0656 (17) & 0.0508 (13) & −0.0296 (14) & 0.0026 (13) & −0.0035 (13) \\
\hline
N31 & 0.0395 (12) & 0.0372 (12) & 0.0444 (13) & −0.0020 (11) & −0.0003 (11) & −0.0003 (10) \\
\hline
C31 & 0.0369 (14) & 0.0423 (15) & 0.0378 (14) & −0.0009 (12) & 0.0027 (11) & −0.0025 (12) \\
\hline
C32 & 0.0476 (17) & 0.061 (2) & 0.0428 (16) & 0.0097 (16) & 0.0065 (14) & −0.0050 (15) \\
\hline
C33 & 0.081 (3) & 0.063 (2) & 0.062 (2) & 0.006 (2) & 0.014 (2) & −0.026 (2) \\
\hline
C34 & 0.053 (2) & 0.118 (4) & 0.071 (3) & 0.021 (3) & 0.009 (2) & −0.022 (3) \\
\hline
C43 & 0.0417 (15) & 0.0330 (13) & 0.0383 (14) & 0.0008 (11) & 0.0043 (12) & 0.0015 (11) \\
\hline
N41 & 0.0410 (12) & 0.0297 (10) & 0.0432 (12) & 0.0017 (10) & 0.0068 (11) & 0.0010 (10) \\
\hline
C41 & 0.0384 (14) & 0.0285 (12) & 0.0518 (17) & 0.0003 (11) & 0.0065 (13) & 0.0025 (12) \\
\hline
C42 & 0.0450 (17) & 0.0422 (16) & 0.0499 (18) & 0.0029 (14) & 0.0035 (14) & 0.0072 (14) \\
\hline
S42 & 0.0482 (4) & 0.0615 (5) & 0.0391 (4) & 0.0057 (4) & 0.0043 (3) & 0.0082 (4) \\
\hline
C44 & 0.0408 (15) & 0.0242 (11) & 0.0568 (18) & −0.0015 (11) & 0.0103 (14) & −0.0020 (12) \\
\hline
O44 & 0.0434 (12) & 0.0416 (11) & 0.0669 (16) & 0.0063 (10) & 0.0086 (12) & 0.0024 (11) \\
\hline
\end{tabular}
\end{table}
|
PMC3254412_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Environment} & \textbf{#Frame} & \textbf{#People} & \textbf{#TP} & \textbf{#FP} & \textbf{Recall (\%)} & \textbf{Precision (\%)} \\
\hline
Morning & 500 & 899 & 464 & 32 & 51.61 & 93.55 \\
\hline
Afternoon & 500 & 730 & 573 & 17 & 78.49 & 97.12 \\
\hline
Night & 500 & 698 & 0 & 0 & 0 & Cannot be calculated \\
\hline
Rainy day & 500 & 559 & 143 & 445 & 25.58 & 24.32 \\
\hline
Total & 2000 & 2886 & 1180 & 494 & 40.89 & 70.49 \\
\hline
\end{tabular}
\end{table}
|
PMC4481953_table_7
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{NL} & \textbf{FL} & \textbf{B} & \textbf{RL} & \textbf{B}-tm & \textbf{B}-tm-cs & \textbf{RL} vs \textbf{FL} & \textbf{RL} vs \textbf{NL} \\
\hline
Hippocampus \\
\hline
Nuclear & 36+, 3− & 6+, 20− & 41+, 0− & 6+, 20− & 17+, 2− & 50+, 0− & 22+, 0− & 5+, 2− \\
\hline
Cytosolic & 23+,14− & 21+,11− & 20+, 3− & 23+, 2− & 7+, 10− & 21+,5− & 3+, 5− & 11+, 4− \\
\hline
Membrane & 8+, 6− & 3+, 9− & 6+, 2− & 6+, 7− & 4+, 5− & 9+, 5− & 7+, 0− & 3+, 0− \\
\hline
Cortex \\
\hline
Nuclear & 14+, 13− & 7+,20− & 20+, 5− & 9+, 38− & 14+, 8− & 19+, 0− & 2+,10− & 2+, 13− \\
\hline
Cytosolic & 25+, 13− & 6+, 10− & 30+, 12− & 19+, 19− & 15+, 12− & 28+, 3− & 7+, 4− & 10+,4− \\
\hline
Membrane & 3+, 12− & 4+, 7− & 6+, 12− & 2+, 20− & 19+, 4− & 16+, 0− & 3+, 6− & 3+, 1− \\
\hline
\end{tabular}
\end{table}
|
PMC4368539_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{M. tuberculosis strains} & \multicolumn{3}{c|}{\textbf{(mM) MIC}} & \textbf{Amino acid change} \\
\hline
& \textbf{1} & \textbf{5} & \textbf{8} \\
\hline
H37Rv wild-type & 3.6 & 0.\textbf{1}6 & 0.04 & – \\
\hline
DR\textbf{1} & \textbf{1}4.\textbf{5} & \textbf{5}.4 & 0.66 & V6\textbf{8}\textbf{1}I \\
\hline
DR2 & \textbf{1}4.\textbf{5} & \textbf{5}.4 & 0.66 & V6\textbf{8}\textbf{1}I \\
\hline
DR3 & \textbf{1}4.\textbf{5} & \textbf{5}.4 & 0.66 & V6\textbf{8}\textbf{1}I S\textbf{8}7P \\
\hline
DR4 & \textbf{1}4.\textbf{5} & \textbf{5}.4 & 0.66 & V6\textbf{8}\textbf{1}I V\textbf{5}\textbf{8}\textbf{1}A N36\textbf{5}S \\
\hline
DR\textbf{5} & \textbf{1}4.\textbf{5} & 2.7 & 0.66 & G2\textbf{5}3E D46G \\
\hline
DR6 & \textbf{1}4.\textbf{5} & \textbf{5}.4 & 0.66 & V6\textbf{8}\textbf{1}I M492T V\textbf{5}64A \\
\hline
DR7 & \textbf{1}4.\textbf{5} & 0.6\textbf{8} & 0.\textbf{1}6 & Q40R \\
\hline
DR\textbf{8} & \textbf{1}4.\textbf{5} & 2.7 & 0.33 & G2\textbf{5}3E I\textbf{5}\textbf{1}6T \\
\hline
DR9 & \textbf{1}4.\textbf{5} & \textbf{1}.3\textbf{5} & 0.33 & V240M R73\textbf{5}C \\
\hline
M. bovis BCG strains \\
\hline
M. bovis BCG wild-type & \textbf{1}.\textbf{8}\textbf{8} & 0.0\textbf{8} & 0.04 & – \\
\hline
M\textbf{1} & \textbf{1}\textbf{5}.04 & 2.6 & 0.63 & L320R E466K I\textbf{5}\textbf{8}\textbf{5}V \\
\hline
M\textbf{8} & \textbf{1}\textbf{5}.0 & 2.6 & 0.63 & L320P S2\textbf{5}\textbf{8}G \\
\hline
\end{tabular}
\end{table}
|
PMC3578785_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{HIV+} & \textbf{HIV-} & \textbf{p value} \\
\hline
Verbal memory VLT RAI & 5.37 & 5.98 & 0.13 \\
\hline
Verbal memory Delayed recall & 5.19 & 5.78 & 0.02* \\
\hline
Symbol Digit & 18.70 & 20.28 & 0.13 \\
\hline
Verbal Fluency & 10.06 & 11.31 & ,0.01* \\
\hline
Digit Span Forward & 5.84 & 6.46 & ,0.01* \\
\hline
Digit Span Backward & 3.37 & 3.16 & 0.20 \\
\hline
Color Trails 1 (seconds) & 146.50 & 104.84 & ,0.00* \\
\hline
Color Trails 2 (seconds) & 211.09 & 182.47 & ,0.00* \\
\hline
\end{tabular}
\end{table}
|
PMC3435287_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
N11—H11···O1A & 0.892 (18) & 1.831 (18) & 2.6305 (17) & 148.1 (16) \\
\hline
N11—H11···O22A & 0.892 (18) & 2.356 (18) & 2.996 (2) & 128.8 (14) \\
\hline
N14—H14B···O1Bi & 0.88 (2) & 1.98 (2) & 2.8181 (19) & 157.3 (17) \\
\hline
N14—H14A···O1B & 0.92 (2) & 1.99 (2) & 2.7962 (18) & 146.4 (18) \\
\hline
N14—H14A···O22B & 0.92 (2) & 2.28 (2) & 2.992 (2) & 133.9 (16) \\
\hline
C5A—H5A···O21Aii & 0.917 (19) & 2.476 (19) & 3.383 (2) & 170.3 (16) \\
\hline
C5B—H5B···O21Biii & 0.913 (18) & 2.487 (18) & 3.394 (2) & 172.3 (15) \\
\hline
C11A—H11C···O41Aiv & 0.93 (3) & 2.48 (3) & 3.345 (2) & 155 (2) \\
\hline
C11A—H11A···O62Aiii & 0.94 (3) & 2.57 (3) & 3.496 (3) & 168 (2) \\
\hline
C12—H12A···O22A & 0.96 (2) & 2.56 (2) & 3.046 (2) & 111.6 (15) \\
\hline
C13—H13A···O62Bv & 0.96 (2) & 2.46 (2) & 3.386 (2) & 162.9 (17) \\
\hline
\end{tabular}
\end{table}
|
PMC3051773_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
& \textbf{n (\%)} \\
\hline
Presence of any mental illness & 56 (70.9) \\
\hline
Subjects with psychiatric diagnosis in the past month & 44 (55.7) \\
\hline
Mood disorders & 24 (30.4) \\
\hline
Past major depressive disorder & 8 \\
\hline
Current major depressive disorder & 5 \\
\hline
With psychotic features & 2 \\
\hline
Without psychotic features & 3 \\
\hline
Dysthymia & 15 \\
\hline
Depressive disorder NOS & 3 \\
\hline
Bipolar disorder & 1 \\
\hline
Alcohol abuse/ dependence & 20 (25.3) \\
\hline
Past alcohol abuse/ dependence & 8 \\
\hline
Current alcohol dependence & 8 \\
\hline
Current alcohol abuse & 4 \\
\hline
Substance abuse/dependence, substance-induced mood, anxiety, or psychotic disorder & 20 (25.3) \\
\hline
Past history of substance abuse/ dependence & 5 \\
\hline
Opiate abuse/ dependence & 18 (22.8) \\
\hline
Past history of opiate dependence & 3 \\
\hline
Current opiate dependence & 15 \\
\hline
Current sedative/ amphetamine/ cough mixture/ cocaine/ cannabis dependence & 11 \\
\hline
Current substance-induced psychotic disorder & 4 \\
\hline
Current substance-induced mood disorder & 2 \\
\hline
Current substance-induced anxiety disorder & 1 \\
\hline
Psychotic disorders & 8 (10.1) \\
\hline
Schizophrenia & 3 \\
\hline
Schizoaffective & 1 \\
\hline
Psychotic disorder NOS & 4 \\
\hline
Anxiety disorders & 8 (10.1) \\
\hline
Past history of obsessive compulsive disorder & 2 \\
\hline
Panic disorder & 2 \\
\hline
Specific phobia & 2 \\
\hline
Anxiety disorder NOS & 1 \\
\hline
Obsessive compulsive disorder & 1 \\
\hline
Dementia & 5 (6.3) \\
\hline
Mild grade intellectual disability & 2 (2.5) \\
\hline
Two or more psychiatric comorbidities & 18 (22.8) \\
\hline
\end{tabular}
\end{table}
|
PMC4618481_table_4
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& & \textbf{Effects} & \textbf{References} \\
\hline
\multirow{6}{*}{Glucocorticoids} & Adult Acute exposure & levels (rodent, non-human ↑ primate, and human) & Zuloaga et al., 2014; Madden et al., 2005; Harris et al., 2003 \\
\hline
Adult repeated exposure & Alterations in circadian rhythm (rat) & Morimasa et al., 1987; Li et al., 2013 \\
\hline
& Decreased basal levels during withdrawal (human) \\
\hline
Developmental acute exposure & levels (mouse and rat) ↑ & Grace et al., 2008; Acevedo et al., 2008 \\
\hline
Developmental repeated exposure & Neonatal exposure: No effects or subtle following adult ↑ stressor (rat) & Grace et al., 2012 \\
\hline
& Prenatal Exposure: No effect on basal levels (rat) Elevated stress induced levels in 2 year olds (human) & Cabrera et al., 1993; Kirlic et al., 2013 \\
\hline
\multirow{4}{*}{HPA axis associated genes/proteins} & CRF & Adult exposure: in CEA and ↑ NAC (rat) & Nawata et al., 2012; Cadet et al., 2014 \\
\hline
AVP & Neonatal/Juvenile exposure: Lasting decreases in AVP-expressing cells in the PVN (mouse) & Zuloaga et al., 2013; Joca et al., 2014. \\
\hline
GR & Adult exposure: in ↓ hippocampus, hypothalamus, and striatum (rat) & Lowy and Novotney, 1994 \\
\hline
MR & Adult exposure: in ↓ hippocampus (rat) & Lowy, 1990 \\
\hline
\multirow{7}{*}{Stress-associated behaviors} & Anxiety-related & Prenatal exposure: No effects (rat) in 3–5 year olds (human) ↑ & Hruba et al., 2012; LaGasse et al., 2012 \\
\hline
& Neonatal exposure: Subtle↑ or found in adulthood, depends ↓ on timing and dose (rat) & Williams et al., 2003; Hruba et al., 2012 \\
\hline
& No effects (mouse) & Eastwood et al., 2012; \\
\hline
& Adult exposure: during ↑ withdrawal (rat, human) & Nawata et al., 2012; London et al., 2004 \\
\hline
Depressive-related & Prenatal exposure: in 3–5 ↑ year olds (human) & LaGasse et al., 2012 \\
\hline
& Juvenile exposure: in ↑ adulthood (mouse) & Joca et al., 2014 \\
\hline
& Adult exposure: during ↑ withdrawal (rat, human) & Jang et al., 2013; Li et al., 2013 \\
\hline
\end{tabular}
\end{table}
|
PMC4444766_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\multicolumn{2}{c|}{\textbf{Falling ADLs}} & \multicolumn{2}{c|}{Non-\textbf{Falling ADLs}} \\
\hline
\textbf{\textbf{No.}} & \textbf{\textbf{Action}} & \textbf{\textbf{No.}} & \textbf{\textbf{Action}} \\
\hline
1 & Slip and ascending stairs & 11 & Ascending stairs \\
\hline
2 & Slip and descending stairs & 12 & Descending stairs \\
\hline
3 & Forward fall & 13 & Sitting down on bed \\
\hline
4 & Backward fall & 14 & Standing up from bed \\
\hline
5 & Falling down from bed & 15 & Sitting down in wheelchair \\
\hline
6 & Fall down from wheelchair & 16 & Standing up from wheelchair \\
\hline
7 & Rolling down from bed & 17 & Walking \\
\hline
8 & Lateral fall & 18 & Lying down \\
\hline
9 & Falling down to bed & 19 & Lying up \\
\hline
\multirow{2}{*}{10} & Fall for the weak leg & 20 & Squatting down \\
\hline
& 21 & Standing up \\
\hline
\end{tabular}
\end{table}
|
PMC3478840_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Radiographs} & \textbf{Anatomic landmarks} & \textbf{Intact side} & \textbf{Injured side} \\
\hline
\multirow{2}{*}{AP view} & ASIS & XA,YA & X’A,Y’A \\
\hline
ischial tuberosity & XB,YB & X’B,Y’B \\
\hline
\multirow{4}{*}{Outlet view} & superior point of iliac wing & XC,YC & X’C,Y’C \\
\hline
ischial tuberosity & XD,YD & X’D,Y’D \\
\hline
ASIS & XE,YE & X’E,Y’E \\
\hline
center of sacral endplate & XS,YS \\
\hline
\multirow{3}{*}{Inlet view} & ASIS & XG,YG & X’G,Y’G \\
\hline
anterior SI joint (iliac side) & XH,YH & X’H,Y’H \\
\hline
center of sacral endplate & XS,YS \\
\hline
\end{tabular}
\end{table}
|
PMC4588254_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{number} & \textbf{Tube type} & \textbf{Spin time (minutes)} & \textbf{Transfer} & \textbf{Ship} & \textbf{Ship} temperature & \textbf{Laboratory} & \textbf{Test} \\
\hline
& SST Gold top (5 mL) & 15 & None & Serum & Ambient & MPHL & Lipid profile \\
\hline
& EDTA Lavender top (4 mL) & 15 & Plasma to 1 transfer tube & Plasma & Cold & LabCorp & Homocysteine \\
\hline
and 4 & EDTA Lavender top (4 mL) & No spin & None & Whole blood & Cold & LabCorp & Hemoglobin A1c; complete blood count \\
\hline
& Red top (10 mL) & 15 & Serum to 2 transfer tubes & Serum & Cold & LabCorp & Insulin; nicotine and metabolite \\
\hline
& SST red/gray top (8.5 mL) & 15 & None & Serum & Cold & LabCorp & Metabolic panel; high sensitivity CRP \\
\hline
\end{tabular}
\end{table}
|
PMC4382458_table_3
|
|
\begi\textbf{\textbf{n}}{table}
\ce\textbf{\textbf{n}}teri\textbf{\textbf{n}}g
\label{tab:tablelabel}
\begi\textbf{\textbf{n}}{tabular}{|l|l|l|l|l|l|l|}
\hli\textbf{\textbf{n}}e
\textbf{Aspects Assessed} & \multicolum\textbf{\textbf{n}}{2}{c|}{\textbf{Ugu District (N = 25)}} & \multicolum\textbf{\textbf{n}}{2}{c|}{\textbf{Uthu\textbf{\textbf{n}}gulu District (N = 27)}} & \multicolum\textbf{\textbf{n}}{2}{c|}{\textbf{Overall}} \\
\hli\textbf{\textbf{n}}e
& \textbf{\textbf{n}} & \textbf{\textbf{\textbf{\%}}} & \textbf{\textbf{n}} & \textbf{\textbf{\textbf{\%}}} & \textbf{Total} & \textbf{\textbf{\textbf{\%}}} \\
\hli\textbf{\textbf{n}}e
Staff members use perso\textbf{\textbf{n}}al protectio\textbf{\textbf{n}} duri\textbf{\textbf{n}}g sputum i\textbf{\textbf{n}}ductio\textbf{\textbf{n}} & 17 & 68.0 & 18 & 66.7 & 35 & 67.3 \\
\hli\textbf{\textbf{n}}e
Masks (N95) are available for use by staff members i\textbf{\textbf{n}} risk areas & 23 & 92.0* & 21 & 77.8 & 44 & 84.9 \\
\hli\textbf{\textbf{n}}e
Staff members trai\textbf{\textbf{n}}ed about TB i\textbf{\textbf{n}}fectio\textbf{\textbf{n}} co\textbf{\textbf{n}}trol practices & 20 & 80.0 & 23 & 85.2* & 43 & 82.6 \\
\hli\textbf{\textbf{n}}e
Records are kept about the trai\textbf{\textbf{n}}i\textbf{\textbf{n}}g co\textbf{\textbf{n}}ducted & 18 & 72.0* & 15 & 55.6 & 33 & 63.8 \\
\hli\textbf{\textbf{n}}e
Staff members are scree\textbf{\textbf{n}}ed for TB & 22 & 88.0 & 24 & 88.9 & 46 & 88.4 \\
\hli\textbf{\textbf{n}}e
Iso\textbf{\textbf{n}}iazid preve\textbf{\textbf{n}}tive therapy is available to HIV-i\textbf{\textbf{n}}fected staff members & 25 & 100.0 & 27 & 100.0 & 52 & 100.0 \\
\hli\textbf{\textbf{n}}e
Facilities reporti\textbf{\textbf{n}}g a staff member i\textbf{\textbf{n}}fected with TB duri\textbf{\textbf{n}}g the last 3 years & 10 & 40.0 & 8 & 29.6 & 24 & 52.2 \\
\hli\textbf{\textbf{n}}e
\e\textbf{\textbf{n}}d{tabular}
\e\textbf{\textbf{n}}d{table}
|
PMC4369348_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{\textbf{Soil} type} & \multicolumn{3}{c|}{\textbf{Zn source}} & \multicolumn{3}{c|}{\textbf{testa F}} \\
\hline
& \textbf{ZnSO4} & \textbf{ZnO} & \textbf{Average} & \textbf{Soil} & \textbf{Source} & \textbf{Soil}*\textbf{Source} \\
\hline
& \multicolumn{6}{c|}{fruitsb plant-1) Young (g} \\
\hline
Sandy loam & 63 & 31 & 47 A & \multirow{2}{*}{**} & \multirow{2}{*}{*} & \multirow{2}{*}{ns} \\
\hline
Clay & 9 & 5 & 7 B \\
\hline
\multirow{2}{*}{\textbf{Average}} & 36 a & 18 b \\
\hline
\multicolumn{6}{c|}{plant-1) Total DM (g} \\
\hline
Sandy loam & 530 & 438 & 484 A & \multirow{2}{*}{**} & \multirow{2}{*}{*} & \multirow{2}{*}{ns} \\
\hline
Clay & 295 & 282 & 289 B \\
\hline
\textbf{Average} & 413 a & 360 b \\
\hline
\end{tabular}
\end{table}
|
PMC4353711_table_1
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Nuclear Score 0} & \textbf{Nuclear Score >0} & \textbf{Nuclear Score 0}-3 & \textbf{Nuclear Score 4+} \\
\hline
ER +ve & 9 & 13 & 17 & 5 \\
\hline
\multirow{2}{*}{ER -ve} & 4 & 14 & 10 & 8 \\
\hline
\multicolumn{2}{c|}{p = 0. 36 (Fishers Exact Test)} & \multicolumn{2}{c|}{p = 0.26 (Fishers Exact Test)} \\
\hline
PR +ve & 4 & 10 & 10 & 4 \\
\hline
\multirow{2}{*}{PR -ve} & 8 & 17 & 16 & 9 \\
\hline
\multicolumn{2}{c|}{p = 1.0 (Fishers Exact Test)} & \multicolumn{2}{c|}{p = 0.92 (Fishers Exact Test)} \\
\hline
\end{tabular}
\end{table}
|
PMC3073906_table_2
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Single} & \textbf{Double} & \textbf{Triple} & \textbf{Quadruple} & \textbf{Quintuple} & \textbf{Sextuple or more} & \textbf{Total} \\
\hline
\multicolumn{2}{c|}{All facial movements} \\
\hline
24 & 482 & 251 & 93 & 37 & 5 & 1 & 869 \\
\hline
weeks & 55.5\% & 28.9\% & 10.7\% & 4.3\% & 0.6\% & 0.1\% \\
\hline
28 & 336 & 319 & 240 & 107 & 24 & 11 & 1037 \\
\hline
weeks & 32.4\% & 30.8\% & 23.1\% & 10.3\% & 2.3\% & 1.1\% \\
\hline
32 & 145 & 245 & 235 & 130 & 28 & 10 & 793 \\
\hline
weeks & 18.3\% & 30.9\% & 29.6\% & 16.4\% & 3.5\% & 1.3\% \\
\hline
36 & 35 & 151 & 236 & 186 & 44 & 3 & 655 \\
\hline
weeks & 5.3\% & 23.1\% & 36.0\% & 28.4\% & 6.7\% & 0.5\% \\
\hline
\end{tabular}
\end{table}
|
PMC3673977_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Toxin} & \textbf{Source} & \textbf{Mechanism} & \textbf{Sensor} & \textbf{effect sensed by NLR (direct or indirect)} & \textbf{Reference} \\
\hline
Lethal toxin (LT) & B. anthracis & Protease & NLRP1 & NLRP1 cleavage & (19–24) \\
\hline
Nigericin & S. hygroscopicus & Ionophore & NLRP3 & K+ efflux & (40) \\
\hline
α-Hemolysin & S. aureus & Pore former & NLRP3 & K+ efflux & (60–62) \\
\hline
Panton-valentine leukocidin & S. aureus & Pore former & NLRP3 & K+ efflux & (68) \\
\hline
Leukocidin A/B & S. aureus & Pore former & NLRP3 & K+ efflux & (69) \\
\hline
Listeriolysin O & L. monocytogenes & Pore former & NLRP3 & K+ efflux & (42, 43, 50) \\
\hline
Aerolysin & A. hydrophila & Pore former & NLRP3 & K+ efflux & (44) \\
\hline
Tetanolysin O & C. tetani & Pore former & NLRP3 & K+ efflux & (49) \\
\hline
Pneumolysin & S. pneumonia & Pore former & NLRP3 & K+ efflux & (51–53) \\
\hline
β-Hemolysin & Group B Streptococcus & Pore former & NLRP3 & K+ efflux & (55–57) \\
\hline
Streptolysin O & S. pyogenes & Pore former & NLRP3 & K+ efflux & (58, 59) \\
\hline
α-Hemolysin & E. coli & Pore former & NLRP3 & K+ efflux & (77) \\
\hline
Enterohemolysin & E. coli O157:H7 & Pore former & NLRP3 & K+ efflux & (76) \\
\hline
Various hemolysins & Vibrio species & Pore former & NLRP3 & K+ efflux & (78–80) \\
\hline
TcdB & C. difficile & Glucosylase & Pyrin & Rho GTPase inactivation & (87, 90) \\
\hline
VopS & V. parahaemolyticus & Adenylyltransferase & Pyrin & Rho GTPase inactivation & (87) \\
\hline
IbpA & H. somni & Adenylyltransferase & Pyrin & Rho GTPase inactivation & (87) \\
\hline
C3 toxin & C. botulinum & ADP-ribosyltransferase & Pyrin & Rho GTPase inactivation & (87) \\
\hline
Unknown & B. cenocepacia & Deamidase & Pyrin & Rho GTPase inactivation & (87) \\
\hline
Pertussis toxin (PTX) & B. pertussis & ADP-ribosyltransferase & Pyrin & Unknown & (87) \\
\hline
CdtB & Aggregatibacter actinomycetemcomitans & Lipid phosphatase & NLRP3 & GSK3β-induced P2X7 activation & (92, 93) \\
\hline
IpaH7.8 & S. flexneri & E3 ubiquitin ligase & NLRP3, NLRC4 & GLMN degradation & (94) \\
\hline
Pertussis adenylate cyclase toxin & B. pertussis & Adenylate cyclase and pore former & NLRP3 & Pore formation; K+ efflux & (98) \\
\hline
Heat-labile enterotoxin (LT) & E. coli & ADP-ribosyltransferase & NLRP3 & cAMP increase & (100, 101) \\
\hline
Cholera toxin (CT) & V. cholerae & ADP-ribosyltransferase & Unknown & cAMP increase & (101) \\
\hline
\end{tabular}
\end{table}
|
PMC4639612_table_0
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Serial number} & \textbf{Seeding Source (Laboratory names of Individual bacterial isolates)} & \textbf{BOD mg/L} \\
\hline
1 & BODSEED & 1999 \\
\hline
2 & Isolate 1 & 100 \\
\hline
3 & Isolate 2 & 893 \\
\hline
4 & Isolate 3 & 260 \\
\hline
5 & Isolate 4 & 580 \\
\hline
6 & Isolate 5 & 1526 \\
\hline
7 & Isolate 6 & 1886 \\
\hline
8 & Isolate 7 & 1273 \\
\hline
9 & Isolate 8 & 426 \\
\hline
10 & Isolate 9 & 1000 \\
\hline
11 & Isolate 10 & 1530 \\
\hline
12 & Isolate 11 & 1875 \\
\hline
13 & Isolate 12 & 1840 \\
\hline
14 & Isolate 13 & 2185 \\
\hline
15 & Isolate 14 & 1605 \\
\hline
16 & Isolate 15 & 1230 \\
\hline
17 & Isolate 16 & 1245 \\
\hline
18 & Isolate 17 & 1175 \\
\hline
19 & Isolate 18 & 235 \\
\hline
20 & Isolate 19 & 560 \\
\hline
21 & Isolate 20 & 104 \\
\hline
22 & Isolate 21 & 369 \\
\hline
23 & Isolate 22 & 489 \\
\hline
24 & Isolate 23 & 1287 \\
\hline
25 & Isolate 24 & 1111 \\
\hline
26 & Isolate 25 & 1210 \\
\hline
\end{tabular}
\end{table}
|
PMC3432350_table_3
|
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
C2—H2A···N2 & 0.98 & 2.60 & 2.950 (17) & 101.0 \\
\hline
C4—H4C···N1 & 0.97 & 2.45 & 2.908 (18) & 108.0 \\
\hline
C5—H5A···N2 & 0.97 & 2.62 & 2.959 (18) & 101.0 \\
\hline
C5—H5B···N1 & 0.97 & 2.53 & 2.903 (16) & 103.0 \\
\hline
C6—H6A···Br1vii & 0.98 & 2.85 & 3.820 (13) & 169.0 \\
\hline
C6—H6B···Br1viii & 0.98 & 2.91 & 3.671 (13) & 136.0 \\
\hline
\end{tabular}
\end{table}
|
PMC3011467_table_4
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.